ID ACACB_HUMAN Reviewed; 2458 AA. AC O00763; A6NK36; Q16852; Q1HEC1; Q6KE87; Q6KE89; Q6TY48; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 05-OCT-2010, sequence version 3. DT 28-JAN-2026, entry version 224. DE RecName: Full=Acetyl-CoA carboxylase 2 {ECO:0000305}; DE EC=6.4.1.2 {ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; DE AltName: Full=ACC-beta; DE Flags: Precursor; GN Name=ACACB {ECO:0000312|HGNC:HGNC:85}; Synonyms=ACC2, ACCB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY. RC TISSUE=Liver; RX PubMed=9099716; DOI=10.1074/jbc.272.16.10669; RA Abu-Elheiga L., Almarza-Ortega D.B., Baldini A., Wakil S.J.; RT "Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, RT chromosomal mapping, and evidence for two isoforms."; RL J. Biol. Chem. 272:10669-10677(1997). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, COFACTOR, RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND RP VARIANT ILE-2141. RX PubMed=16854592; DOI=10.1016/j.pep.2006.06.005; RA Cheng D., Chu C.-H., Chen L., Feder J.N., Mintier G.A., Wu Y., Cook J.W., RA Harpel M.R., Locke G.A., An Y., Tamura J.K.; RT "Expression, purification, and characterization of human and rat acetyl RT coenzyme A carboxylase (ACC) isozymes."; RL Protein Expr. Purif. 51:11-21(2007). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT ILE-2141. RC TISSUE=Heart; RA Peng X.R., Lindgren K., Corneliussen B.; RT "Corrected sequence for human acetyl-CoA carboxylase 2 obtained by RT alignment to human genomic DNA and PCR cloning from human skeletal muscle RT and heart cDNA."; RL Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases. RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RC TISSUE=Heart; RA Mao J., Wakil S.J.; RT "Alternative splicing in the human acetyl-CoA carboxylase 2 (ACC2) gene."; RL Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16541075; DOI=10.1038/nature04569; RA Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y., RA Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C., RA Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C., RA Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., RA Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E., RA Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., RA Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., RA Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., RA Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., RA Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., RA Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., RA Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., RA Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., RA Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., RA Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K., RA Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D., RA Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R., RA David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E., RA D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N., RA Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N., RA Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R., RA Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S., RA LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H., RA Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P., RA Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G., RA Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E., RA Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S., RA Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., RA Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J., RA Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A., RA Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M., RA Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I., RA Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A., RA Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y., RA Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A., RA Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F., RA Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L., RA Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G., RA Gibbs R.A.; RT "The finished DNA sequence of human chromosome 12."; RL Nature 440:346-351(2006). RN [6] RP NUCLEOTIDE SEQUENCE [MRNA] OF 1324-2109. RC TISSUE=Adipose tissue; RX PubMed=8670171; DOI=10.1042/bj3160915; RA Widmer J., Fassihi K.S., Schlichter S.C., Wheeler K.S., Crute B.E., RA King N., Nutile-Mcmenemy N., Noll W.W., Daniel S., Ha J., Kim K.-H., RA Witters L.A.; RT "Identification of a second human acetyl-CoA carboxylase gene."; RL Biochem. J. 316:915-922(1996). RN [7] RP SUBCELLULAR LOCATION. RX PubMed=10677481; DOI=10.1073/pnas.97.4.1444; RA Abu-Elheiga L., Brinkley W.R., Zhong L., Chirala S.S., Woldegiorgis G., RA Wakil S.J.; RT "The subcellular localization of acetyl-CoA carboxylase 2."; RL Proc. Natl. Acad. Sci. U.S.A. 97:1444-1449(2000). RN [8] RP PHOSPHORYLATION AT SER-222 BY AMPK, AND ACTIVITY REGULATION. RX PubMed=12488245; DOI=10.1152/ajpendo.00436.2002; RA Wojtaszewski J.F., MacDonald C., Nielsen J.N., Hellsten Y., Hardie D.G., RA Kemp B.E., Kiens B., Richter E.A.; RT "Regulation of 5'AMP-activated protein kinase activity and substrate RT utilization in exercising human skeletal muscle."; RL Am. J. Physiol. 284:E813-E822(2003). RN [9] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP BIOPHYSICOCHEMICAL PROPERTIES, CATALYTIC ACTIVITY, AND FUNCTION. RX PubMed=19236960; DOI=10.1016/j.bbapap.2009.02.004; RA Kaushik V.K., Kavana M., Volz J.M., Weldon S.C., Hanrahan S., Xu J., RA Caplan S.L., Hubbard B.K.; RT "Characterization of recombinant human acetyl-CoA carboxylase-2 steady- RT state kinetics."; RL Biochim. Biophys. Acta 1794:961-967(2009). RN [11] RP BIOPHYSICOCHEMICAL PROPERTIES, ALTERNATIVE SPLICING (ISOFORM 3), AND TISSUE RP SPECIFICITY. RX PubMed=19190759; DOI=10.1371/journal.pone.0004369; RA Castle J.C., Hara Y., Raymond C.K., Garrett-Engele P., Ohwaki K., Kan Z., RA Kusunoki J., Johnson J.M.; RT "ACC2 is expressed at high levels in human white adipose and has an isoform RT with a novel N-terminus."; RL PLoS ONE 4:E4369-E4369(2009). RN [12] RP FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBUNIT, AND INTERACTION RP WITH MID1IP1. RX PubMed=20457939; DOI=10.1073/pnas.1001292107; RA Kim C.W., Moon Y.A., Park S.W., Cheng D., Kwon H.J., Horton J.D.; RT "Induced polymerization of mammalian acetyl-CoA carboxylase by MIG12 RT provides a tertiary level of regulation of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:9626-9631(2010). RN [13] RP CATALYTIC ACTIVITY, SUBUNIT, ACTIVITY REGULATION, AND INTERACTION WITH RP MID1IP1. RX PubMed=20952656; DOI=10.1073/pnas.1012736107; RA Colbert C.L., Kim C.W., Moon Y.A., Henry L., Palnitkar M., McKean W.B., RA Fitzgerald K., Deisenhofer J., Horton J.D., Kwon H.J.; RT "Crystal structure of Spot 14, a modulator of fatty acid synthesis."; RL Proc. Natl. Acad. Sci. U.S.A. 107:18820-18825(2010). RN [14] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-35; THR-70; SER-91; SER-95; RP SER-200; SER-469 AND THR-1342, AND IDENTIFICATION BY MASS SPECTROMETRY RP [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [15] RP X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 217-775. RX PubMed=17876819; DOI=10.1002/prot.21611; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Cheon Y.H., Seo C.I., Kim Y.E., RA Hyun Y.L., Lee Y.S., Sugiyama K., Park S.Y., Ro S., Cho J.M., Lee T.G., RA Heo Y.S.; RT "Crystal structure of the biotin carboxylase domain of human acetyl-CoA RT carboxylase 2."; RL Proteins 70:268-272(2008). RN [16] RP STRUCTURE BY NMR OF 885-971. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of RSGI RUH-053, an apo-biotin carboxy carrier protein RT from human transcarboxylase."; RL Submitted (OCT-2006) to the PDB data bank. RN [17] RP STRUCTURE BY NMR OF 891-965, BIOTINYLATION AT LYS-929, COFACTOR, AND RP DOMAIN. RX PubMed=18247344; DOI=10.1002/prot.21952; RA Lee C.K., Cheong H.K., Ryu K.S., Lee J.I., Lee W., Jeon Y.H., Cheong C.; RT "Biotinoyl domain of human acetyl-CoA carboxylase: Structural insights into RT the carboxyl transfer mechanism."; RL Proteins 72:613-624(2008). RN [18] RP X-RAY CRYSTALLOGRAPHY (3.19 ANGSTROMS) OF 1693-2450 IN COMPLEX WITH RP INHIBITOR, AND DOMAIN. RX PubMed=19390150; DOI=10.1107/s0907444909008014; RA Madauss K.P., Burkhart W.A., Consler T.G., Cowan D.J., Gottschalk W.K., RA Miller A.B., Short S.A., Tran T.B., Williams S.P.; RT "The human ACC2 CT-domain C-terminus is required for full functionality and RT has a novel twist."; RL Acta Crystallogr. D 65:449-461(2009). RN [19] RP X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 217-775 IN COMPLEX WITH SORAPHEN RP A, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, PATHWAY, SUBUNIT, RP PHOSPHORYLATION AT SER-222, AND MUTAGENESIS OF ARG-277 AND GLU-671. RX PubMed=19900410; DOI=10.1016/j.bbrc.2009.11.029; RA Cho Y.S., Lee J.I., Shin D., Kim H.T., Jung H.Y., Lee T.G., Kang L.W., RA Ahn Y.J., Cho H.S., Heo Y.S.; RT "Molecular mechanism for the regulation of human ACC2 through RT phosphorylation by AMPK."; RL Biochem. Biophys. Res. Commun. 391:187-192(2010). RN [20] RP X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 238-760 IN COMPLEX WITH RP INHIBITOR, FUNCTION, CATALYTIC ACTIVITY, AND PATHWAY. RX PubMed=26976583; DOI=10.1073/pnas.1520686113; RA Harriman G., Greenwood J., Bhat S., Huang X., Wang R., Paul D., Tong L., RA Saha A.K., Westlin W.F., Kapeller R., Harwood H.J. Jr.; RT "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, RT improves insulin sensitivity, and modulates dyslipidemia in rats."; RL Proc. Natl. Acad. Sci. U.S.A. 113:E1796-E1805(2016). RN [21] RP VARIANT [LARGE SCALE ANALYSIS] LEU-193. RX PubMed=18772397; DOI=10.1126/science.1164368; RA Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., RA Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., RA Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., RA Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., RA Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., RA Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., RA Velculescu V.E., Kinzler K.W.; RT "Core signaling pathways in human pancreatic cancers revealed by global RT genomic analyses."; RL Science 321:1801-1806(2008). CC -!- FUNCTION: Mitochondrial enzyme that catalyzes the carboxylation of CC acetyl-CoA to malonyl-CoA and plays a central role in fatty acid CC metabolism (PubMed:16854592, PubMed:19236960, PubMed:19900410, CC PubMed:20457939, PubMed:20952656, PubMed:26976583). Catalyzes a 2 steps CC reaction starting with the ATP-dependent carboxylation of the biotin CC carried by the biotin carboxyl carrier (BCC) domain followed by the CC transfer of the carboxyl group from carboxylated biotin to acetyl-CoA CC (PubMed:19236960, PubMed:20457939, PubMed:20952656, PubMed:26976583). CC Through the production of malonyl-CoA that allosterically inhibits CC carnitine palmitoyltransferase 1 at the mitochondria, negatively CC regulates fatty acid oxidation (By similarity). Together with its CC cytosolic isozyme ACACA, which is involved in de novo fatty acid CC biosynthesis, promotes lipid storage (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19236960, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656, CC ECO:0000269|PubMed:26976583}. CC -!- CATALYTIC ACTIVITY: CC Reaction=hydrogencarbonate + acetyl-CoA + ATP = malonyl-CoA + ADP + CC phosphate + H(+); Xref=Rhea:RHEA:11308, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17544, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, CC ChEBI:CHEBI:57288, ChEBI:CHEBI:57384, ChEBI:CHEBI:456216; EC=6.4.1.2; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:19236960, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000269|PubMed:20952656, ECO:0000269|PubMed:26976583}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:11309; CC Evidence={ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:26976583}; CC -!- COFACTOR: CC Name=biotin; Xref=ChEBI:CHEBI:57586; CC Evidence={ECO:0000269|PubMed:16854592, ECO:0000269|PubMed:18247344}; CC -!- COFACTOR: CC Name=Mg(2+); Xref=ChEBI:CHEBI:18420; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Name=Mn(2+); Xref=ChEBI:CHEBI:29035; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00409, CC ECO:0000255|PROSITE-ProRule:PRU00969}; CC Note=Binds 2 magnesium or manganese ions per subunit. CC {ECO:0000255|PROSITE-ProRule:PRU00409, ECO:0000255|PROSITE- CC ProRule:PRU00969}; CC -!- ACTIVITY REGULATION: Activity is increased by oligomerization of the CC protein into filaments (PubMed:19900410). The oligomerization and the CC activity of the enzyme are inhibited by phosphorylation at Ser-222 CC (PubMed:12488245). Inhibited by its product, malonyl-CoA CC (PubMed:16854592). Activated by citrate (PubMed:16854592). Activation CC by MID1IP1 is citrate-dependent (PubMed:20457939). Soraphen A, inhibits CC the enzyme by preventing the formation of active filamentous oligomers CC (Probable). {ECO:0000269|PubMed:12488245, ECO:0000269|PubMed:16854592, CC ECO:0000269|PubMed:19900410, ECO:0000269|PubMed:20457939, CC ECO:0000305|PubMed:19236960}. CC -!- BIOPHYSICOCHEMICAL PROPERTIES: CC Kinetic parameters: CC KM=120 uM for ATP {ECO:0000269|PubMed:16854592}; CC KM=110 uM for ATP (isoform 2) {ECO:0000269|PubMed:19190759}; CC KM=58 uM for acetyl-CoA {ECO:0000269|PubMed:16854592}; CC KM=94 uM for acetyl-CoA (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=6.5 mM for NaHCO3 (isoform 3) {ECO:0000269|PubMed:19190759}; CC KM=3.0 mM for NaHCO(3) {ECO:0000269|PubMed:16854592}; CC pH dependence: CC Optimum pH is 7.5. {ECO:0000305|PubMed:19236960}; CC -!- PATHWAY: Lipid metabolism; malonyl-CoA biosynthesis; malonyl-CoA from CC acetyl-CoA: step 1/1. {ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:26976583}. CC -!- SUBUNIT: Monomer, homodimer, and homotetramer (PubMed:18772397, CC PubMed:20952656). Forms filamentous polymers (PubMed:19900410, CC PubMed:20457939, PubMed:20952656). Interacts with MID1IP1; interaction CC with MID1IP1 promotes oligomerization and increases its activity in a CC citrate-dependent manner (PubMed:20457939, PubMed:20952656). CC {ECO:0000269|PubMed:18772397, ECO:0000269|PubMed:19900410, CC ECO:0000269|PubMed:20457939, ECO:0000269|PubMed:20952656}. CC -!- INTERACTION: CC O00763; O00763: ACACB; NbExp=2; IntAct=EBI-2211739, EBI-2211739; CC O00763; P50747: HLCS; NbExp=4; IntAct=EBI-2211739, EBI-3915568; CC O00763; Q9CQ20: Mid1ip1; Xeno; NbExp=4; IntAct=EBI-2211739, EBI-473024; CC -!- SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10677481}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=3; CC Name=1; Synonyms=Long; CC IsoId=O00763-1; Sequence=Displayed; CC Name=2; Synonyms=Short; CC IsoId=O00763-2; Sequence=VSP_000547; CC Name=3 {ECO:0000305}; Synonyms=ACC2.v2 {ECO:0000303|PubMed:19190759}; CC IsoId=O00763-3; Sequence=VSP_057081, VSP_057082; CC -!- TISSUE SPECIFICITY: Widely expressed with highest levels in heart, CC skeletal muscle, liver, adipose tissue, mammary gland, adrenal gland CC and colon (PubMed:9099716). Isoform 3 is expressed in skeletal muscle, CC adipose tissue and liver (at protein level) (PubMed:19190759). Isoform CC 3 is detected at high levels in adipose tissue with lower levels in CC heart, liver, skeletal muscle and testis (PubMed:19190759). CC {ECO:0000269|PubMed:19190759, ECO:0000269|PubMed:9099716}. CC -!- DOMAIN: Consists of an N-terminal biotin carboxylation/carboxylase (BC) CC domain that catalyzes the ATP-dependent transient carboxylation of the CC biotin covalently attached to the central biotinyl-binding/biotin CC carboxyl carrier (BCC) domain (Probable). The C-terminal carboxyl CC transferase (CT) domain catalyzes the transfer of the carboxyl group CC from carboxylated biotin to acetyl-CoA to produce malonyl-CoA CC (Probable). {ECO:0000305|PubMed:18247344, ECO:0000305|PubMed:19390150}. CC -!- PTM: The biotin cofactor is covalently attached to the central CC biotinyl-binding domain and is required for the catalytic activity. CC {ECO:0000305|PubMed:18247344}. CC -!- PTM: Phosphorylation at Ser-222 by AMPK inactivates the enzyme CC (PubMed:12488245). Required for the maintenance of skeletal muscle CC lipid and glucose homeostasis (By similarity). CC {ECO:0000250|UniProtKB:E9Q4Z2, ECO:0000269|PubMed:12488245}. CC -!- BIOTECHNOLOGY: Inhibition of ACACB may prevent lipid-induced insulin CC resistance and type 2 diabetes, making the enzyme a potential CC pharmaceutical target for treatment of obesity and type 2 diabetes. CC {ECO:0000305}. CC -!- SEQUENCE CAUTION: CC Sequence=AAB58382.1; Type=Miscellaneous discrepancy; Note=Many Frameshifts and conflicts.; Evidence={ECO:0000305}; CC Sequence=CAE01470.2; Type=Erroneous translation; Note=Wrong choice of CDS.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U89344; AAB58382.1; ALT_SEQ; mRNA. DR EMBL; DQ493870; ABF48723.1; -; mRNA. DR EMBL; AJ575431; CAE01470.2; ALT_SEQ; mRNA. DR EMBL; AJ575592; CAE01471.3; -; mRNA. DR EMBL; AY382667; AAR37018.1; -; mRNA. DR EMBL; AC007637; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; U34591; AAC50571.1; -; mRNA. DR CCDS; CCDS31898.1; -. [O00763-1] DR PIR; S71091; S71091. DR RefSeq; NP_001084.3; NM_001093.4. [O00763-1] DR RefSeq; NP_001399663.1; NM_001412734.1. [O00763-1] DR RefSeq; NP_001399664.1; NM_001412735.1. [O00763-1] DR RefSeq; NP_001399665.1; NM_001412736.1. [O00763-3] DR PDB; 2DN8; NMR; -; A=885-971. DR PDB; 2HJW; X-ray; 2.50 A; A=217-775. DR PDB; 2KCC; NMR; -; A=891-965. DR PDB; 3FF6; X-ray; 3.19 A; A/B/C/D=1693-2450. DR PDB; 3GID; X-ray; 2.30 A; A/B=238-760. DR PDB; 3GLK; X-ray; 2.10 A; A=238-760. DR PDB; 3JRW; X-ray; 2.60 A; A=217-775. DR PDB; 3JRX; X-ray; 2.50 A; A=217-775. DR PDB; 3TDC; X-ray; 2.41 A; A=1690-2445. DR PDB; 4HQ6; X-ray; 2.70 A; A=217-776. DR PDB; 5KKN; X-ray; 2.60 A; B/C=238-760. DR PDBsum; 2DN8; -. DR PDBsum; 2HJW; -. DR PDBsum; 2KCC; -. DR PDBsum; 3FF6; -. DR PDBsum; 3GID; -. DR PDBsum; 3GLK; -. DR PDBsum; 3JRW; -. DR PDBsum; 3JRX; -. DR PDBsum; 3TDC; -. DR PDBsum; 4HQ6; -. DR PDBsum; 5KKN; -. DR AlphaFoldDB; O00763; -. DR SMR; O00763; -. DR BioGRID; 106550; 180. DR DIP; DIP-51617N; -. DR FunCoup; O00763; 2599. DR IntAct; O00763; 69. DR MINT; O00763; -. DR STRING; 9606.ENSP00000341044; -. DR BindingDB; O00763; -. DR ChEMBL; CHEMBL4829; -. DR DrugBank; DB03781; 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid. DR DrugBank; DB00173; Adenine. DR DrugBank; DB00121; Biotin. DR DrugBank; DB07870; Haloxyfop-P. DR DrugBank; DB00331; Metformin. DR DrugBank; DB12096; PF-05175157. DR DrugBank; DB02859; Soraphen A. DR GuidetoPHARMACOLOGY; 1264; -. DR SwissLipids; SLP:000000730; -. DR GlyGen; O00763; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; O00763; -. DR PhosphoSitePlus; O00763; -. DR BioMuta; ACACB; -. DR jPOST; O00763; -. DR MassIVE; O00763; -. DR PaxDb; 9606-ENSP00000341044; -. DR PeptideAtlas; O00763; -. DR ProteomicsDB; 48022; -. [O00763-1] DR ProteomicsDB; 48023; -. [O00763-2] DR Antibodypedia; 1321; 163 antibodies from 30 providers. DR DNASU; 32; -. DR Ensembl; ENST00000338432.12; ENSP00000341044.7; ENSG00000076555.16. [O00763-1] DR Ensembl; ENST00000377848.7; ENSP00000367079.3; ENSG00000076555.16. [O00763-1] DR GeneID; 32; -. DR KEGG; hsa:32; -. DR MANE-Select; ENST00000338432.12; ENSP00000341044.7; NM_001093.4; NP_001084.3. DR UCSC; uc001tob.4; human. [O00763-1] DR AGR; HGNC:85; -. DR ClinPGx; PA24422; -. DR CTD; 32; -. DR DisGeNET; 32; -. DR GeneCards; ACACB; -. DR HGNC; HGNC:85; ACACB. DR HPA; ENSG00000076555; Tissue enhanced (adipose tissue, skeletal muscle). DR MalaCards; ACACB; -. DR MIM; 601557; gene. DR OpenTargets; ENSG00000076555; -. DR VEuPathDB; HostDB:ENSG00000076555; -. DR eggNOG; KOG0368; Eukaryota. DR GeneTree; ENSGT00940000155049; -. DR HOGENOM; CLU_000395_5_0_1; -. DR InParanoid; O00763; -. DR OMA; TEHCKVA; -. DR OrthoDB; 14612at2759; -. DR PAN-GO; O00763; 3 GO annotations based on evolutionary models. DR PhylomeDB; O00763; -. DR BioCyc; MetaCyc:HS01211-MONOMER; -. DR BRENDA; 6.3.4.14; 2681. DR BRENDA; 6.4.1.2; 2681. DR PathwayCommons; O00763; -. DR Reactome; R-HSA-163765; ChREBP activates metabolic gene expression. DR Reactome; R-HSA-196780; Biotin transport and metabolism. DR Reactome; R-HSA-200425; Carnitine shuttle. DR Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP). DR SABIO-RK; O00763; -. DR SignaLink; O00763; -. DR SIGNOR; O00763; -. DR UniPathway; UPA00655; UER00711. DR Agora; ENSG00000076555; -. DR BioGRID-ORCS; 32; 8 hits in 1154 CRISPR screens. DR ChiTaRS; ACACB; human. DR EvolutionaryTrace; O00763; -. DR GeneWiki; ACACB; -. DR GenomeRNAi; 32; -. DR Pharos; O00763; Tchem. DR PRO; PR:O00763; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; O00763; protein. DR Bgee; ENSG00000076555; Expressed in tendon of biceps brachii and 208 other cell types or tissues. DR ExpressionAtlas; O00763; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0016507; C:mitochondrial fatty acid beta-oxidation multienzyme complex; IEA:Ensembl. DR GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome. DR GO; GO:0005739; C:mitochondrion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; IDA:UniProtKB. DR GO; GO:0003989; F:acetyl-CoA carboxylase activity; IDA:UniProtKB. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0009374; F:biotin binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IPI:IntAct. DR GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW. DR GO; GO:0006084; P:acetyl-CoA metabolic process; IDA:UniProtKB. DR GO; GO:0046323; P:D-glucose import; IEA:Ensembl. DR GO; GO:0097009; P:energy homeostasis; IEA:Ensembl. DR GO; GO:0006633; P:fatty acid biosynthetic process; IBA:GO_Central. DR GO; GO:0055089; P:fatty acid homeostasis; TAS:Reactome. DR GO; GO:0019395; P:fatty acid oxidation; IEA:Ensembl. DR GO; GO:0090459; P:intracellular aspartate homeostasis; IEA:Ensembl. DR GO; GO:0090461; P:intracellular glutamate homeostasis; IEA:Ensembl. DR GO; GO:0046722; P:lactic acid secretion; IEA:Ensembl. DR GO; GO:2001295; P:malonyl-CoA biosynthetic process; IEA:UniProtKB-UniPathway. DR GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IEA:Ensembl. DR GO; GO:0006098; P:pentose-phosphate shunt; IEA:Ensembl. DR GO; GO:0060421; P:positive regulation of heart growth; IEA:Ensembl. DR GO; GO:0010884; P:positive regulation of lipid storage; IEA:Ensembl. DR GO; GO:0051289; P:protein homotetramerization; IDA:UniProtKB. DR GO; GO:1903242; P:regulation of cardiac muscle hypertrophy in response to stress; IEA:Ensembl. DR GO; GO:0010906; P:regulation of glucose metabolic process; IEA:Ensembl. DR GO; GO:0061771; P:response to caloric restriction; IEA:Ensembl. DR GO; GO:0007584; P:response to nutrient; IEA:Ensembl. DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl. DR GO; GO:0072350; P:tricarboxylic acid metabolic process; IEA:Ensembl. DR CDD; cd06850; biotinyl_domain; 1. DR FunFam; 2.40.460.10:FF:000001; Acetyl-CoA carboxylase 1; 1. DR FunFam; 2.40.50.100:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.470.20:FF:000005; Acetyl-CoA carboxylase 1; 1. DR FunFam; 3.90.1770.10:FF:000001; acetyl-CoA carboxylase 1; 1. DR FunFam; 3.30.1490.20:FF:000003; acetyl-CoA carboxylase isoform X1; 1. DR FunFam; 3.40.50.20:FF:000005; acetyl-CoA carboxylase isoform X2; 1. DR FunFam; 3.90.226.10:FF:000010; acetyl-CoA carboxylase isoform X2; 1. DR Gene3D; 2.40.50.100; -; 1. DR Gene3D; 3.40.50.20; -; 1. DR Gene3D; 3.90.226.10; 2-enoyl-CoA Hydratase, Chain A, domain 1; 2. DR Gene3D; 3.30.1490.20; ATP-grasp fold, A domain; 1. DR Gene3D; 3.30.470.20; ATP-grasp fold, B domain; 1. DR Gene3D; 2.40.460.10; Biotin dependent carboxylase carboxyltransferase; 1. DR Gene3D; 3.90.1770.10; PreATP-grasp domain; 1. DR InterPro; IPR049076; ACCA. DR InterPro; IPR049074; ACCA_BT. DR InterPro; IPR034733; AcCoA_carboxyl_beta. DR InterPro; IPR013537; AcCoA_COase_cen. DR InterPro; IPR011761; ATP-grasp. DR InterPro; IPR013815; ATP_grasp_subdomain_1. DR InterPro; IPR005481; BC-like_N. DR InterPro; IPR011764; Biotin_carboxylation_dom. DR InterPro; IPR005482; Biotin_COase_C. DR InterPro; IPR000089; Biotin_lipoyl. DR InterPro; IPR029045; ClpP/crotonase-like_dom_sf. DR InterPro; IPR011763; COA_CT_C. DR InterPro; IPR011762; COA_CT_N. DR InterPro; IPR005479; CPAse_ATP-bd. DR InterPro; IPR016185; PreATP-grasp_dom_sf. DR InterPro; IPR011054; Rudment_hybrid_motif. DR InterPro; IPR011053; Single_hybrid_motif. DR PANTHER; PTHR45728:SF1; ACETYL-COA CARBOXYLASE 2; 1. DR PANTHER; PTHR45728; ACETYL-COA CARBOXYLASE, ISOFORM A; 1. DR Pfam; PF08326; ACC_central; 1. DR Pfam; PF21385; ACCA_BT; 1. DR Pfam; PF02785; Biotin_carb_C; 1. DR Pfam; PF00289; Biotin_carb_N; 1. DR Pfam; PF00364; Biotin_lipoyl; 1. DR Pfam; PF01039; Carboxyl_trans; 1. DR Pfam; PF02786; CPSase_L_D2; 1. DR SMART; SM00878; Biotin_carb_C; 1. DR SUPFAM; SSF52096; ClpP/crotonase; 2. DR SUPFAM; SSF56059; Glutathione synthetase ATP-binding domain-like; 1. DR SUPFAM; SSF52440; PreATP-grasp domain; 1. DR SUPFAM; SSF51246; Rudiment single hybrid motif; 1. DR SUPFAM; SSF51230; Single hybrid motif; 1. DR PROSITE; PS50975; ATP_GRASP; 1. DR PROSITE; PS50979; BC; 1. DR PROSITE; PS50968; BIOTINYL_LIPOYL; 1. DR PROSITE; PS50989; COA_CT_CTER; 1. DR PROSITE; PS50980; COA_CT_NTER; 1. DR PROSITE; PS00866; CPSASE_1; 1. DR PROSITE; PS00867; CPSASE_2; 1. PE 1: Evidence at protein level; KW 3D-structure; Allosteric enzyme; Alternative splicing; ATP-binding; Biotin; KW Fatty acid biosynthesis; Fatty acid metabolism; Ligase; Lipid biosynthesis; KW Lipid metabolism; Magnesium; Manganese; Metal-binding; Mitochondrion; KW Multifunctional enzyme; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; Transit peptide. FT TRANSIT 1..? FT /note="Mitochondrion" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT CHAIN ?..2458 FT /note="Acetyl-CoA carboxylase 2" FT /evidence="ECO:0000305" FT /id="PRO_0000146767" FT DOMAIN 259..761 FT /note="Biotin carboxylation" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00969" FT DOMAIN 414..609 FT /note="ATP-grasp" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT DOMAIN 888..962 FT /note="Biotinyl-binding" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066" FT DOMAIN 1695..2025 FT /note="CoA carboxyltransferase N-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01136" FT DOMAIN 2029..2345 FT /note="CoA carboxyltransferase C-terminal" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01137" FT REGION 35..155 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 174..193 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1695..2345 FT /note="Carboxyltransferase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01138" FT COMPBIAS 51..60 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 77..87 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 103..146 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 584 FT /evidence="ECO:0000250" FT BINDING 458..463 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409" FT BINDING 567 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 567 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 580 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mg(2+)" FT /ligand_id="ChEBI:CHEBI:18420" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 582 FT /ligand="Mn(2+)" FT /ligand_id="ChEBI:CHEBI:29035" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00409, FT ECO:0000255|PROSITE-ProRule:PRU00969" FT BINDING 1934 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2238 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT BINDING 2240 FT /ligand="CoA" FT /ligand_id="ChEBI:CHEBI:57287" FT /evidence="ECO:0000250" FT MOD_RES 35 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 70 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 91 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 95 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 169 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 175 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 192 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 195 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 200 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 207 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 220 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:P11497" FT MOD_RES 222 FT /note="Phosphoserine; by AMPK" FT /evidence="ECO:0000269|PubMed:12488245, FT ECO:0000269|PubMed:19900410" FT MOD_RES 469 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 753 FT /note="Phosphothreonine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT MOD_RES 929 FT /note="N6-biotinyllysine" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU01066, FT ECO:0000269|PubMed:18247344" FT MOD_RES 1340 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1342 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 1360 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:E9Q4Z2" FT MOD_RES 1405 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q13085" FT VAR_SEQ 1..202 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057081" FT VAR_SEQ 203..218 FT /note="AYLTTGEAETRVPTMR -> MSPAKCKICFPDREVK (in isoform 3)" FT /evidence="ECO:0000269|PubMed:19190759" FT /id="VSP_057082" FT VAR_SEQ 1118..1187 FT /note="Missing (in isoform 2)" FT /evidence="ECO:0000303|PubMed:9099716" FT /id="VSP_000547" FT VARIANT 193 FT /note="R -> L (in a pancreatic ductal adenocarcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:18772397" FT /id="VAR_062667" FT VARIANT 552 FT /note="I -> V (in dbSNP:rs16940029)" FT /id="VAR_031255" FT VARIANT 651 FT /note="A -> T (in dbSNP:rs2300455)" FT /id="VAR_031256" FT VARIANT 2141 FT /note="V -> I (in dbSNP:rs2075260)" FT /evidence="ECO:0000269|PubMed:16854592, ECO:0000269|Ref.3" FT /id="VAR_031257" FT MUTAGEN 277 FT /note="R->A: Loss of regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT MUTAGEN 671 FT /note="E->A: Altered regulation of oligomerization by FT phosphorylation at S-222." FT /evidence="ECO:0000269|PubMed:19900410" FT CONFLICT 9 FT /note="C -> R (in Ref. 2; ABF48723)" FT /evidence="ECO:0000305" FT CONFLICT 120 FT /note="T -> I (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 422 FT /note="I -> T (in Ref. 4; AAR37018)" FT /evidence="ECO:0000305" FT CONFLICT 1340 FT /note="S -> N (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1383 FT /note="D -> G (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1425 FT /note="V -> M (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1819..1821 FT /note="AEG -> PEA (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT CONFLICT 1892..1893 FT /note="MI -> IM (in Ref. 6; AAC50571)" FT /evidence="ECO:0000305" FT HELIX 247..253 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 262..265 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 269..287 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 292..299 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 301..305 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 309..313 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 325..327 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 328..330 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 332..341 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 345..348 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 353..356 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 359..366 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 370..373 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 376..379 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 385..394 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 403..406 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 426..431 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 437..447 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 449..455 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 464..467 FT /evidence="ECO:0007829|PDB:3GLK" FT TURN 470..472 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 473..483 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 489..493 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 496..507 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 509..511 FT /evidence="ECO:0007829|PDB:3JRX" FT STRAND 513..523 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 524..527 FT /evidence="ECO:0007829|PDB:4HQ6" FT STRAND 530..535 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 541..558 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 562..571 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 576..582 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 589..596 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 600..608 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 613..615 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 617..622 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 635..637 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 646..653 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 669..671 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 679..685 FT /evidence="ECO:0007829|PDB:3GLK" FT STRAND 700..709 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 710..724 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 728..730 FT /evidence="ECO:0007829|PDB:2HJW" FT HELIX 732..742 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 744..748 FT /evidence="ECO:0007829|PDB:3GLK" FT HELIX 754..756 FT /evidence="ECO:0007829|PDB:2HJW" FT STRAND 896..898 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 900..902 FT /evidence="ECO:0007829|PDB:2KCC" FT STRAND 903..910 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 914..916 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 921..927 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 930..935 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 937..944 FT /evidence="ECO:0007829|PDB:2DN8" FT STRAND 957..961 FT /evidence="ECO:0007829|PDB:2DN8" FT TURN 1698..1700 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 1703..1711 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1717..1719 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1720..1732 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1742..1750 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1756..1759 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1767..1777 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1786..1793 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1798..1800 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1804..1820 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1824..1828 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1839..1842 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1846..1850 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1855..1857 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1859..1864 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1866..1872 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1873..1876 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1878..1885 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1888..1896 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1899..1901 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1905..1924 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1927..1931 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1933..1936 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1938..1946 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1948..1952 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1956..1960 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1962..1969 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1977..1981 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1983..1986 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 1987..1990 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 1993..1998 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 1999..2010 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2045..2050 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2055..2057 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2072..2075 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2082..2089 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2092..2099 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2104..2108 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2120..2124 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2131..2147 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2151..2154 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2164..2168 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2171..2183 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2189..2193 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2198..2200 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2201..2205 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2209..2211 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2213..2215 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2216..2221 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2225..2229 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2231..2238 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2241..2251 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2253..2261 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2269..2299 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2300..2302 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2304..2309 FT /evidence="ECO:0007829|PDB:3TDC" FT STRAND 2312..2317 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2319..2321 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2322..2344 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2345..2348 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2352..2365 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2369..2376 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2378..2388 FT /evidence="ECO:0007829|PDB:3TDC" FT HELIX 2404..2420 FT /evidence="ECO:0007829|PDB:3TDC" FT TURN 2423..2425 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2426..2435 FT /evidence="ECO:0007829|PDB:3FF6" FT HELIX 2439..2448 FT /evidence="ECO:0007829|PDB:3FF6" SQ SEQUENCE 2458 AA; 276541 MW; ED12674A1A8A0706 CRC64; MVLLLCLSCL IFSCLTFSWL KIWGKMTDSK PITKSKSEAN LIPSQEPFPA SDNSGETPQR NGEGHTLPKT PSQAEPASHK GPKDAGRRRN SLPPSHQKPP RNPLSSSDAA PSPELQANGT GTQGLEATDT NGLSSSARPQ GQQAGSPSKE DKKQANIKRQ LMTNFILGSF DDYSSDEDSV AGSSRESTRK GSRASLGALS LEAYLTTGEA ETRVPTMRPS MSGLHLVKRG REHKKLDLHR DFTVASPAEF VTRFGGDRVI EKVLIANNGI AAVKCMRSIR RWAYEMFRNE RAIRFVVMVT PEDLKANAEY IKMADHYVPV PGGPNNNNYA NVELIVDIAK RIPVQAVWAG WGHASENPKL PELLCKNGVA FLGPPSEAMW ALGDKIASTV VAQTLQVPTL PWSGSGLTVE WTEDDLQQGK RISVPEDVYD KGCVKDVDEG LEAAERIGFP LMIKASEGGG GKGIRKAESA EDFPILFRQV QSEIPGSPIF LMKLAQHARH LEVQILADQY GNAVSLFGRD CSIQRRHQKI VEEAPATIAP LAIFEFMEQC AIRLAKTVGY VSAGTVEYLY SQDGSFHFLE LNPRLQVEHP CTEMIADVNL PAAQLQIAMG VPLHRLKDIR LLYGESPWGV TPISFETPSN PPLARGHVIA ARITSENPDE GFKPSSGTVQ ELNFRSSKNV WGYFSVAATG GLHEFADSQF GHCFSWGENR EEAISNMVVA LKELSIRGDF RTTVEYLINL LETESFQNND IDTGWLDYLI AEKVQAEKPD IMLGVVCGAL NVADAMFRTC MTDFLHSLER GQVLPADSLL NLVDVELIYG GVKYILKVAR QSLTMFVLIM NGCHIEIDAH RLNDGGLLLS YNGNSYTTYM KEEVDSYRIT IGNKTCVFEK ENDPTVLRSP SAGKLTQYTV EDGGHVEAGS SYAEMEVMKM IMTLNVQERG RVKYIKRPGA VLEAGCVVAR LELDDPSKVH PAEPFTGELP AQQTLPILGE KLHQVFHSVL ENLTNVMSGF CLPEPVFSIK LKEWVQKLMM TLRHPSLPLL ELQEIMTSVA GRIPAPVEKS VRRVMAQYAS NITSVLCQFP SQQIATILDC HAATLQRKAD REVFFINTQS IVQLVQRYRS GIRGYMKTVV LDLLRRYLRV EHHFQQAHYD KCVINLREQF KPDMSQVLDC IFSHAQVAKK NQLVIMLIDE LCGPDPSLSD ELISILNELT QLSKSEHCKV ALRARQILIA SHLPSYELRH NQVESIFLSA IDMYGHQFCP ENLKKLILSE TTIFDVLPTF FYHANKVVCM ASLEVYVRRG YIAYELNSLQ HRQLPDGTCV VEFQFMLPSS HPNRMTVPIS ITNPDLLRHS TELFMDSGFS PLCQRMGAMV AFRRFEDFTR NFDEVISCFA NVPKDTPLFS EARTSLYSED DCKSLREEPI HILNVSIQCA DHLEDEALVP ILRTFVQSKK NILVDYGLRR ITFLIAQEKE FPKFFTFRAR DEFAEDRIYR HLEPALAFQL ELNRMRNFDL TAVPCANHKM HLYLGAAKVK EGVEVTDHRF FIRAIIRHSD LITKEASFEY LQNEGERLLL EAMDELEVAF NNTSVRTDCN HIFLNFVPTV IMDPFKIEES VRYMVMRYGS RLWKLRVLQA EVKINIRQTT TGSAVPIRLF ITNESGYYLD ISLYKEVTDS RSGNIMFHSF GNKQGPQHGM LINTPYVTKD LLQAKRFQAQ TLGTTYIYDF PEMFRQALFK LWGSPDKYPK DILTYTELVL DSQGQLVEMN RLPGGNEVGM VAFKMRFKTQ EYPEGRDVIV IGNDITFRIG SFGPGEDLLY LRASEMARAE GIPKIYVAAN SGARIGMAEE IKHMFHVAWV DPEDPHKGFK YLYLTPQDYT RISSLNSVHC KHIEEGGESR YMITDIIGKD DGLGVENLRG SGMIAGESSL AYEEIVTISL VTCRAIGIGA YLVRLGQRVI QVENSHIILT GASALNKVLG REVYTSNNQL GGVQIMHYNG VSHITVPDDF EGVYTILEWL SYMPKDNHSP VPIITPTDPI DREIEFLPSR APYDPRWMLA GRPHPTLKGT WQSGFFDHGS FKEIMAPWAQ TVVTGRARLG GIPVGVIAVE TRTVEVAVPA DPANLDSEAK IIQQAGQVWF PDSAYKTAQA VKDFNREKLP LMIFANWRGF SGGMKDMYDQ VLKFGAYIVD GLRQYKQPIL IYIPPYAELR GGSWVVIDAT INPLCIEMYA DKESRGGVLE PEGTVEIKFR KKDLIKSMRR IDPAYKKLME QLGEPDLSDK DRKDLEGRLK AREDLLLPIY HQVAVQFADF HDTPGRMLEK GVISDILEWK TARTFLYWRL RRLLLEDQVK QEILQASGEL SHVHIQSMLR RWFVETEGAV KAYLWDNNQV VVQWLEQHWQ AGDGPRSTIR ENITYLKHDS VLKTIRGLVE ENPEVAVDCV IYLSQHISPA ERAQVVHLLS TMDSPAST // ID ALEX_HUMAN Reviewed; 626 AA. AC P84996; A2A2S4; DT 17-OCT-2006, integrated into UniProtKB/Swiss-Prot. DT 17-OCT-2006, sequence version 1. DT 28-JAN-2026, entry version 131. DE RecName: Full=Protein ALEX; DE AltName: Full=Alternative gene product encoded by XL-exon; GN Name=GNAS {ECO:0000312|HGNC:HGNC:4392}; GN Synonyms=GNAS1 {ECO:0000312|HGNC:HGNC:4392}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] {ECO:0000305} RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=11780052; DOI=10.1038/414865a; RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R., RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L., RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P., RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D., RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G., RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E., RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D., RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P., RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E., RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J., RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D., RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S., RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D., RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A., RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T., RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I., RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M., RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D., RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M., RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A., RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L., RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L., RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.; RT "The DNA sequence and comparative analysis of human chromosome 20."; RL Nature 414:865-871(2001). RN [2] {ECO:0000305} RP PUTATIVE FUNCTION, AND VARIANTS THR-374; RP GLN-PRO-ILE-PRO-THR-PRO-GLY-ARG-PRO-LEU-THR-PRO-375 INS AND VAL-397. RX PubMed=12719376; DOI=10.1093/hmg/ddg130; RA Freson K., Jaeken J., Van Helvoirt M., de Zegher F., Wittevrongel C., RA Thys C., Hoylaerts M.F., Vermylen J., Van Geet C.; RT "Functional polymorphisms in the paternally expressed XLalphas and its RT cofactor ALEX decrease their mutual interaction and enhance receptor- RT mediated cAMP formation."; RL Hum. Mol. Genet. 12:1121-1130(2003). RN [3] {ECO:0000305} RP IDENTIFICATION. RX PubMed=15148396; DOI=10.1073/pnas.0308758101; RA Abramowitz J., Grenet D., Birnbaumer M., Torres H.N., Birnbaumer L.; RT "XL alpha-s, the extra-long form of the alpha subunit of the Gs G protein, RT is significantly longer than suspected, and so is its companion Alex."; RL Proc. Natl. Acad. Sci. U.S.A. 101:8366-8371(2004). RN [4] RP INVOLVEMENT IN PHP1B. RX PubMed=11067869; DOI=10.1172/jci10431; RA Liu J., Litman D., Rosenberg M.J., Yu S., Biesecker L.G., Weinstein L.S.; RT "A GNAS1 imprinting defect in pseudohypoparathyroidism type IB."; RL J. Clin. Invest. 106:1167-1174(2000). RN [5] RP INVOLVEMENT IN PHP1B. RX PubMed=11294659; DOI=10.1086/320117; RA Bastepe M., Lane A.H., Jueppner H.; RT "Paternal uniparental isodisomy of chromosome 20q -- and the resulting RT changes in GNAS1 methylation -- as a plausible cause of RT pseudohypoparathyroidism."; RL Am. J. Hum. Genet. 68:1283-1289(2001). RN [6] RP INVOLVEMENT IN PHP1B. RX PubMed=11029463; DOI=10.1074/jbc.m006032200; RA Wu W.-I., Schwindinger W.F., Aparicio L.F., Levine M.A.; RT "Selective resistance to parathyroid hormone caused by a novel uncoupling RT mutation in the carboxyl terminus of G alpha(s). A cause of RT pseudohypoparathyroidism type Ib."; RL J. Biol. Chem. 276:165-171(2001). RN [7] RP INVOLVEMENT IN PHP1B. RX PubMed=12858292; DOI=10.1086/377136; RA Jan de Beur S., Ding C., Germain-Lee E., Cho J., Maret A., Levine M.A.; RT "Discordance between genetic and epigenetic defects in RT pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal RT imprinting at GNAS1."; RL Am. J. Hum. Genet. 73:314-322(2003). RN [8] RP INVOLVEMENT IN AIMAH1. RX PubMed=12727968; DOI=10.1210/jc.2002-021362; RA Fragoso M.C.B.V., Domenice S., Latronico A.C., Martin R.M., Pereira M.A.A., RA Zerbini M.C.N., Lucon A.M., Mendonca B.B.; RT "Cushing's syndrome secondary to adrenocorticotropin-independent RT macronodular adrenocortical hyperplasia due to activating mutations of RT GNAS1 gene."; RL J. Clin. Endocrinol. Metab. 88:2147-2151(2003). RN [9] RP INVOLVEMENT IN PHP1B. RX PubMed=14561710; DOI=10.1172/jci19159; RA Bastepe M., Froehlich L.F., Hendy G.N., Indridason O.S., Josse R.G., RA Koshiyama H., Koerkkoe J., Nakamoto J.M., Rosenbloom A.L., Slyper A.H., RA Sugimoto T., Tsatsoulis A., Crawford J.D., Jueppner H.; RT "Autosomal dominant pseudohypoparathyroidism type Ib is associated with a RT heterozygous microdeletion that likely disrupts a putative imprinting RT control element of GNAS."; RL J. Clin. Invest. 112:1255-1263(2003). RN [10] RP INVOLVEMENT IN PHP1B. RX PubMed=15800843; DOI=10.1086/429932; RA Linglart A., Gensure R.C., Olney R.C., Jueppner H., Bastepe M.; RT "A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type RT Ib redefines the boundaries of a cis-acting imprinting control element of RT GNAS."; RL Am. J. Hum. Genet. 76:804-814(2005). RN [11] RP INVOLVEMENT IN PHP1B. RX PubMed=15592469; DOI=10.1038/ng1487; RA Bastepe M., Froehlich L.F., Linglart A., Abu-Zahra H.S., Tojo K., RA Ward L.M., Jueppner H.; RT "Deletion of the NESP55 differentially methylated region causes loss of RT maternal GNAS imprints and pseudohypoparathyroidism type Ib."; RL Nat. Genet. 37:25-27(2005). RN [12] RP VARIANTS [LARGE SCALE ANALYSIS] CYS-201 AND HIS-201. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). CC -!- FUNCTION: May inhibit the adenylyl cyclase-stimulating activity of CC guanine nucleotide-binding protein G(s) subunit alpha which is produced CC from the same locus in a different open reading frame. CC {ECO:0000269|PubMed:12719376}. CC -!- SUBUNIT: Interacts with the N-terminal region of the XLas isoforms of CC guanine nucleotide-binding protein G(s) subunit alpha. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein. Cell CC projection, ruffle {ECO:0000250}. Note=Predominantly associated with CC cell membrane ruffles. {ECO:0000250}. CC -!- DISEASE: Note=Genetic variation affecting the GNAS locus is associated CC with GNAS hyperfunction, a condition characterized by increased trauma- CC related bleeding tendency, prolonged bleeding time, brachydactyly and CC intellectual disability. Both the XLas isoforms and the ALEX protein CC are mutated which strongly reduces the interaction between them and CC this may allow unimpeded activation of the XLas isoforms. CC {ECO:0000269|PubMed:12719376}. CC -!- DISEASE: ACTH-independent macronodular adrenal hyperplasia 1 (AIMAH1) CC [MIM:219080]: A rare adrenal defect characterized by multiple, CC bilateral, non-pigmented, benign, adrenocortical nodules. It results in CC excessive production of cortisol leading to ACTH-independent Cushing CC syndrome. Clinical manifestations of Cushing syndrome include facial CC and truncal obesity, abdominal striae, muscular weakness, osteoporosis, CC arterial hypertension, diabetes. {ECO:0000269|PubMed:12727968}. CC Note=The disease is caused by variants affecting the gene represented CC in this entry. CC -!- DISEASE: Pseudohypoparathyroidism 1B (PHP1B) [MIM:603233]: A disorder CC characterized by end-organ resistance to parathyroid hormone, CC hypocalcemia and hyperphosphatemia. Patients affected with PHP1B lack CC developmental defects characteristic of Albright hereditary CC osteodystrophy, and typically show no other endocrine abnormalities CC besides resistance to PTH. {ECO:0000269|PubMed:11029463, CC ECO:0000269|PubMed:11067869, ECO:0000269|PubMed:11294659, CC ECO:0000269|PubMed:12858292, ECO:0000269|PubMed:14561710, CC ECO:0000269|PubMed:15592469, ECO:0000269|PubMed:15800843}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. Most affected individuals have defects in methylation of the CC gene. In some cases microdeletions involving the STX16 appear to cause CC loss of methylation at exon A/B of GNAS, resulting in PHP1B. Paternal CC uniparental isodisomy have also been observed. CC -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease CC characterized by malignant lesions arising from the inner wall of the CC large intestine (the colon) and the rectum. Genetic alterations are CC often associated with progression from premalignant lesion (adenoma) to CC invasive adenocarcinoma. Risk factors for cancer of the colon and CC rectum include colon polyps, long-standing ulcerative colitis, and CC genetic family history. Note=The disease may be caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: This protein is produced by a bicistronic gene which CC also produces guanine nucleotide-binding protein G(s) subunit alpha CC from an overlapping reading frame. {ECO:0000269|PubMed:15148396}. CC -!- SIMILARITY: Belongs to the ALEX family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AL132655; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR RefSeq; NP_001070958.1; NM_001077490.3. DR RefSeq; NP_001296812.1; NM_001309883.1. DR AlphaFoldDB; P84996; -. DR BioGRID; 109040; 280. DR IntAct; P84996; 9. DR MINT; P84996; -. DR iPTMnet; P84996; -. DR SwissPalm; P84996; -. DR BioMuta; GNAS; -. DR DMDM; 116242967; -. DR MassIVE; P84996; -. DR ProteomicsDB; 57761; -. DR Antibodypedia; 4152; 801 antibodies from 43 providers. DR DNASU; 2778; -. DR GeneID; 2778; -. DR UCSC; uc061ybz.1; human. DR AGR; HGNC:4392; -. DR CIViC; 2778; 15 evidence items across 8 molecular profiles. DR ClinPGx; PA175; -. DR CTD; 2778; -. DR DisGeNET; 2778; -. DR GeneCards; GNAS; -. DR GeneReviews; GNAS; -. DR HGNC; HGNC:4392; GNAS. DR MalaCards; GNAS; -. DR MIM; 114500; phenotype. DR MIM; 139320; gene. DR MIM; 219080; phenotype. DR MIM; 603233; phenotype. DR VEuPathDB; HostDB:ENSG00000087460; -. DR HOGENOM; CLU_437395_0_0_1; -. DR OrthoDB; 9836061at2759; -. DR PathwayCommons; P84996; -. DR SignaLink; P84996; -. DR BioGRID-ORCS; 2778; 33 hits in 1176 CRISPR screens. DR ChiTaRS; GNAS; human. DR GenomeRNAi; 2778; -. DR Pharos; P84996; Tbio. DR Proteomes; UP000005640; Chromosome 20. DR Bgee; ENSG00000087460; Expressed in type B pancreatic cell and 215 other cell types or tissues. DR ExpressionAtlas; P84996; baseline and differential. DR GO; GO:0005829; C:cytosol; IDA:UniProtKB. DR GO; GO:0016020; C:membrane; IDA:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell. DR GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell. DR GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0060348; P:bone development; IMP:UniProtKB. DR GO; GO:0050890; P:cognition; IMP:UniProtKB. DR GO; GO:0048589; P:developmental growth; IMP:UniProtKB. DR GO; GO:0060789; P:hair follicle placode formation; IMP:UniProtKB. DR GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB. DR GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab. DR GO; GO:0009966; P:regulation of signal transduction; IMP:CACAO. PE 1: Evidence at protein level; KW Cell membrane; Cell projection; Cushing syndrome; Disease variant; KW Membrane; Proteomics identification; Reference proteome. FT CHAIN 1..626 FT /note="Protein ALEX" FT /id="PRO_0000253964" FT REGION 1..29 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 173..223 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 236..473 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 556..612 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 186..195 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 255..270 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 281..312 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 337..346 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 366..399 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 416..435 FT /note="Low complexity" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 436..445 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 570..579 FT /note="Basic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 600..611 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT VARIANT 201 FT /note="R -> C (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035788" FT VARIANT 201 FT /note="R -> H (in a colorectal cancer sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_035789" FT VARIANT 374 FT /note="P -> T (found in GNAS hyperfunction; FT dbSNP:rs1376506169)" FT /evidence="ECO:0000269|PubMed:12719376" FT /id="VAR_028774" FT VARIANT 375 FT /note="P -> PQPIPTPGRPLTP (found in GNAS hyperfunction)" FT /id="VAR_028775" FT VARIANT 397 FT /note="L -> V (found in GNAS hyperfunction)" FT /evidence="ECO:0000269|PubMed:12719376" FT /id="VAR_028776" SQ SEQUENCE 626 AA; 67948 MW; F4CEFA7FA5917EEC CRC64; MMARPVDPQR SPDPTFRSST RHSGKLEPME ATAHLLRKQC PSRLNSPAWE ASGLHWSSLD SPVGSMQALR PSAQHSWSPE PSVVPDQAWE DTALHQKKLC PLSLTSLPRE AAVNFSYRSQ TLLQEAQVLQ GSPELLPRSP KPSGLQRLAP EEATALPLRR LCHLSLMEKD LGTTAHPRGF PELSHKSTAA ASSRQSRPRV RSASLPPRTR LPSGSQAPSA AHPKRLSDLL LTSRAAAPGW RSPDPRSRLA APPLGSTTLP STWTAPQSRL TARPSRSPEP QIRESEQRDP QLRRKQQRWK EPLMPRREEK YPLRGTDPLP PGQPQRIPLP GQPLQPQPIL TPGQPQKIPT PGQHQPILTP GHSQPIPTPG QPLPPQPIPT PGRPLTPQPI PTPGRPLTPQ PIQMPGRPLR LPPPLRLLRP GQPMSPQLRQ TQGLPLPQPL LPPGQPKSAG RPLQPLPPGP DARSISDPPA PRSRLPIRLL RGLLARLPGG ASPRAAAAAA CTTMKGWPAA TMTPAETSPT MGPPDASAGF SIGEIAAAES PSATYSATFS CKPSGAASVD LRVPSPKPRA LSRSRRYPWR RSADRCAKKP WRSGPRSAQR RNAVSSSTNN SRTKRWATCV RTACCF // ID NTRK2_HUMAN Reviewed; 822 AA. AC Q16620; B1ANZ4; B4DFV9; Q16675; Q59GJ1; Q8WXJ5; Q8WXJ6; Q8WXJ7; DT 01-NOV-1997, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 28-JAN-2026, entry version 249. DE RecName: Full=BDNF/NT-3 growth factors receptor; DE EC=2.7.10.1 {ECO:0000269|PubMed:15494731}; DE AltName: Full=GP145-TrkB; DE Short=Trk-B; DE AltName: Full=Neurotrophic tyrosine kinase receptor type 2; DE AltName: Full=TrkB tyrosine kinase; DE AltName: Full=Tropomyosin-related kinase B; DE Flags: Precursor; GN Name=NTRK2; Synonyms=TRKB; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB). RC TISSUE=Hippocampus; RX PubMed=7789988; DOI=10.1016/0888-7543(95)80055-q; RA Nakagawara A., Liu X.-G., Ikegaki N., White P.S., Yamashiro D.J., RA Nycum L.M., Biegel J.A., Brodeur G.M.; RT "Cloning and chromosomal localization of the human TRK-B tyrosine kinase RT receptor gene (NTRK2)."; RL Genomics 25:538-546(1995). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB AND TRKB-T1). RC TISSUE=Brain; RX PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995; RA Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P., RA Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.; RT "Human trks: molecular cloning, tissue distribution, and expression of RT extracellular domain immunoadhesins."; RL J. Neurosci. 15:477-491(1995). RN [3] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), TISSUE SPECIFICITY, AND RP DEVELOPMENTAL STAGE. RC TISSUE=Hippocampus; RX PubMed=7936202; DOI=10.1016/0306-4522(94)90507-x; RA Allen S.J., Dawbarn D., Eckford S.D., Wilcock G.K., Ashcroft M., RA Colebrook S.M., Feeney R., Macgowan S.H.; RT "Cloning of a non-catalytic form of human trkB and distribution of RT messenger RNA for trkB in human brain."; RL Neuroscience 60:825-834(1994). RN [4] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS TRKB; TRKB-T1; TRKB-T-SHC; 4 AND 5), RP ALTERNATIVE SPLICING, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION. RX PubMed=11798182; DOI=10.1006/bbrc.2001.6301; RA Stoilov P., Castren E., Stamm S.; RT "Analysis of the human TrkB gene genomic organization reveals novel TrkB RT isoforms, unusual gene length, and splicing mechanism."; RL Biochem. Biophys. Res. Commun. 290:1054-1065(2002). RN [5] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKB-T1), AND VARIANT ARG-309. RA Steinbeck J.A., Thomsen S., Wessig J., Leypoldt F., Lewerenz J., RA Methner A.; RT "Full length truncated TrkB sequence identified in a screen for genes RT regulated by ischemic preconditioning."; RL Submitted (MAY-2002) to the EMBL/GenBank/DDBJ databases. RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-N-T1). RC TISSUE=Amygdala; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [7] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T-TK). RC TISSUE=Brain; RA Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S., RA Ohara O., Nagase T., Kikuno R.F.; RT "Homo sapiens protein coding cDNA."; RL Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases. RN [8] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=15164053; DOI=10.1038/nature02465; RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L., RA Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R., RA Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S., RA Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K., RA Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y., RA Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C., RA Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E., RA Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M., RA Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J., RA Frankish A., Frankland J.A., French L., Fricker D.G., Garner P., RA Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S., RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E., RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D., RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E., RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K., RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S., RA Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J., RA Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E., RA McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V., RA Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S., RA Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K., RA Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J., RA Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., RA West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L., RA Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M., RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J., RA Dunham I.; RT "DNA sequence and analysis of human chromosome 9."; RL Nature 429:369-374(2004). RN [9] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [10] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKB-T1). RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [11] RP FUNCTION, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-67; ASN-95; ASN-121; RP ASN-178; ASN-205; ASN-241; ASN-254; ASN-280; ASN-338 AND ASN-412. RX PubMed=7574684; DOI=10.1006/abbi.1995.1460; RA Haniu M., Talvenheimo J., Le J., Katta V., Welcher A., Rohde M.F.; RT "Extracellular domain of neurotrophin receptor trkB: disulfide structure, RT N-glycosylation sites, and ligand binding."; RL Arch. Biochem. Biophys. 322:256-264(1995). RN [12] RP INTERACTION WITH FRS2. RX PubMed=10092678; DOI=10.1074/jbc.274.14.9861; RA Meakin S.O., MacDonald J.I.S., Gryz E.A., Kubu C.J., Verdi J.M.; RT "The signaling adapter FRS-2 competes with Shc for binding to the nerve RT growth factor receptor TrkA. A model for discriminating proliferation and RT differentiation."; RL J. Biol. Chem. 274:9861-9870(1999). RN [13] RP GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-67; ASN-121 AND ASN-254. RC TISSUE=Plasma; RX PubMed=16335952; DOI=10.1021/pr0502065; RA Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E., Moore R.J., RA Smith R.D.; RT "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, RT hydrazide chemistry, and mass spectrometry."; RL J. Proteome Res. 4:2070-2080(2005). RN [14] RP ALTERNATIVE SPLICING (ISOFORMS TRKB-T-TK AND TRKB-N-T1). RX PubMed=20193039; DOI=10.1111/j.1471-4159.2010.06662.x; RA Luberg K., Wong J., Weickert C.S., Timmusk T.; RT "Human TrkB gene: novel alternative transcripts, protein isoforms and RT expression pattern in the prefrontal cerebral cortex during postnatal RT development."; RL J. Neurochem. 113:952-964(2010). RN [15] {ECO:0007744|PDB:1WWB} RP X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 283-385, AND DISULFIDE BONDS. RX PubMed=10388563; DOI=10.1006/jmbi.1999.2816; RA Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D., RA Bass S.H., de Vos A.M.; RT "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and RT TrkC."; RL J. Mol. Biol. 290:149-159(1999). RN [16] {ECO:0007744|PDB:1HCF} RP X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 284-383 IN COMPLEX WITH NTF4, AND RP DISULFIDE BONDS. RX PubMed=11738045; DOI=10.1016/s0969-2126(01)00681-5; RA Banfield M.J., Naylor R.L., Robertson A.G., Allen S.J., Dawbarn D., RA Brady R.L.; RT "Specificity in Trk receptor:neurotrophin interactions: the crystal RT structure of TrkB-d5 in complex with neurotrophin-4/5."; RL Structure 9:1191-1199(2001). RN [17] RP INTERACTION WITH SLITRK2. RX PubMed=35840571; DOI=10.1038/s41467-022-31566-z; RA El Chehadeh S., Han K.A., Kim D., Jang G., Bakhtiari S., Lim D., Kim H.Y., RA Kim J., Kim H., Wynn J., Chung W.K., Vitiello G., Cutcutache I., Page M., RA Gecz J., Harper K., Han A.R., Kim H.M., Wessels M., Bayat A., Jaen A.F., RA Selicorni A., Maitz S., de Brouwer A.P.M., Silfhout A.V., Armstrong M., RA Symonds J., Kuery S., Isidor B., Cogne B., Nizon M., Feger C., Muller J., RA Torti E., Grange D.K., Willems M., Kruer M.C., Ko J., Piton A., Um J.W.; RT "SLITRK2 variants associated with neurodevelopmental disorders impair RT excitatory synaptic function and cognition in mice."; RL Nat. Commun. 13:4112-4112(2022). RN [18] RP VARIANT OBHD CYS-706, CHARACTERIZATION OF VARIANT OBHD CYS-706, FUNCTION AS RP A BDNF-ACTIVATED RECEPTOR, CATALYTIC ACTIVITY, PHOSPHORYLATION, AND RP SUBCELLULAR LOCATION. RX PubMed=15494731; DOI=10.1038/nn1336; RA Yeo G.S., Connie Hung C.C., Rochford J., Keogh J., Gray J., RA Sivaramakrishnan S., O'Rahilly S., Farooqi I.S.; RT "A de novo mutation affecting human TrkB associated with severe obesity and RT developmental delay."; RL Nat. Neurosci. 7:1187-1189(2004). RN [19] RP VARIANT [LARGE SCALE ANALYSIS] PHE-138. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [20] RP VARIANTS ILE-697; GLY-699 AND CYS-718. RX PubMed=18293376; DOI=10.1002/humu.20707; RA Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C., RA Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F., RA Camplese P., D'Antuono T., Sacco R., Buttitta F.; RT "Frequent mutations in the neurotrophic tyrosine receptor kinase gene RT family in large cell neuroendocrine carcinoma of the lung."; RL Hum. Mutat. 29:609-616(2008). RN [21] RP VARIANT OBHD 444-GLY--GLY-822 DEL. RX PubMed=27884935; DOI=10.1136/jmedgenet-2016-104215; RA Miller K.A., Twigg S.R., McGowan S.J., Phipps J.M., Fenwick A.L., RA Johnson D., Wall S.A., Noons P., Rees K.E., Tidey E.A., Craft J., RA Taylor J., Taylor J.C., Goos J.A., Swagemakers S.M., Mathijssen I.M., RA van der Spek P.J., Lord H., Lester T., Abid N., Cilliers D., Hurst J.A., RA Morton J.E., Sweeney E., Weber A., Wilson L.C., Wilkie A.O.; RT "Diagnostic value of exome and whole genome sequencing in RT craniosynostosis."; RL J. Med. Genet. 54:260-268(2017). RN [22] RP VARIANT DEE58 CYS-434, VARIANT OBHD ILE-704, AND INVOLVEMENT IN DEE58. RX PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008; RG Deciphering Developmental Disorders Study; RA Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D., RA Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M., RA Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W., RA Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C., RA Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N., RA Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A., RA Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q., RA Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N., RA Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K., RA Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C., RA Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S., RA Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G., RA O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C., RA Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R., RA Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M., RA Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G., RA Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z., RA Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C., RA Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E., RA Minassian B.A., Michaud J.L.; RT "High rate of recurrent de novo mutations in developmental and epileptic RT encephalopathies."; RL Am. J. Hum. Genet. 101:664-685(2017). CC -!- FUNCTION: Receptor tyrosine kinase involved in the development and the CC maturation of the central and the peripheral nervous systems through CC regulation of neuron survival, proliferation, migration, CC differentiation, and synapse formation and plasticity (By similarity). CC Receptor for BDNF/brain-derived neurotrophic factor and CC NTF4/neurotrophin-4. Alternatively can also bind NTF3/neurotrophin-3 CC which is less efficient in activating the receptor but regulates neuron CC survival through NTRK2 (PubMed:15494731, PubMed:7574684). Upon ligand- CC binding, undergoes homodimerization, autophosphorylation and activation CC (PubMed:15494731). Recruits, phosphorylates and/or activates several CC downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that CC regulate distinct overlapping signaling cascades. Through SHC1, FRS2, CC SH2B1, SH2B2 activates the GRB2-Ras-MAPK cascade that regulates for CC instance neuronal differentiation including neurite outgrowth. Through CC the same effectors controls the Ras-PI3 kinase-AKT1 signaling cascade CC that mainly regulates growth and survival. Through PLCG1 and the CC downstream protein kinase C-regulated pathways controls synaptic CC plasticity. Thereby, plays a role in learning and memory by regulating CC both short term synaptic function and long-term potentiation. PLCG1 CC also leads to NF-Kappa-B activation and the transcription of genes CC involved in cell survival. Hence, it is able to suppress anoikis, the CC apoptosis resulting from loss of cell-matrix interactions. May also CC play a role in neutrophin-dependent calcium signaling in glial cells CC and mediate communication between neurons and glia. CC {ECO:0000250|UniProtKB:P15209, ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:7574684}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA- CC COMP:20101, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858, CC ChEBI:CHEBI:61978, ChEBI:CHEBI:456216; EC=2.7.10.1; CC Evidence={ECO:0000255|PROSITE-ProRule:PRU10028, CC ECO:0000269|PubMed:15494731}; CC -!- ACTIVITY REGULATION: The neuronal activity and the influx of calcium CC positively regulate the kinase activity and the internalization of the CC receptor which are both important for active signaling. Regulated by CC NGFR that may control the internalization of the receptor. NGFR may CC also stimulate the activation by BDNF compared to NTF3 and NTF4. SH2D1A CC inhibits the autophosphorylation of the receptor, and alters the CC recruitment and activation of downstream effectors and signaling CC cascades. The formation of active receptors dimers able to fully CC transduce the ligand-mediated signal, may be negatively regulated by CC the formation of inactive heterodimers with the non-catalytic isoforms CC (By similarity). {ECO:0000250|UniProtKB:P15209, CC ECO:0000250|UniProtKB:Q63604}. CC -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low CC affinity) and dimeric (high affinity) structures. Interacts CC (phosphorylated upon activation by BDNF) with SHC1; mediates SHC1 CC phosphorylation and activation. Interacts (phosphorylated upon CC activation by BDNF) with PLCG1 and/or PLCG2; mediates PLCG1 CC phosphorylation and activation. Interacts with SH2B1 and SH2B2. CC Interacts with NGFR; may regulate the ligand specificity of the CC receptor (By similarity). Interacts with SORCS2; this interaction is CC important for normal targeting to post-synaptic densities in response CC to high-frequency stimulation (By similarity). Interacts CC (phosphorylated upon ligand-binding) with SH2D1A; regulates NTRK2. CC Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts CC (phosphorylated upon ligand-binding) with FRS2; activates the MAPK CC signaling pathway (PubMed:10092678). Interacts with APPL1 (By CC similarity). Interacts with MAPK8IP3/JIP3 and KLC1; interaction with CC KLC1 is mediated by MAPK8IP3/JIP3 (By similarity). Interacts with CC SORL1; this interaction facilitates NTRK2 trafficking between synaptic CC plasma membranes, postsynaptic densities and cell soma, hence CC positively regulates BDNF signaling (By similarity). Interacts with CC SLITRK2 (PubMed:35840571). {ECO:0000250|UniProtKB:P04629, CC ECO:0000250|UniProtKB:P15209, ECO:0000250|UniProtKB:Q63604, CC ECO:0000269|PubMed:10092678, ECO:0000269|PubMed:11738045, CC ECO:0000269|PubMed:35840571}. CC -!- INTERACTION: CC Q16620; P00533: EGFR; NbExp=3; IntAct=EBI-3904881, EBI-297353; CC Q16620; Q16288: NTRK3; NbExp=3; IntAct=EBI-3904881, EBI-3936704; CC Q16620; Q13485: SMAD4; NbExp=4; IntAct=EBI-3904881, EBI-347263; CC Q16620; Q03114: Cdk5; Xeno; NbExp=3; IntAct=EBI-3904881, EBI-2008531; CC -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15494731}; CC Single-pass type I membrane protein {ECO:0000305}. Endosome membrane CC {ECO:0000250|UniProtKB:P15209}; Single-pass type I membrane protein CC {ECO:0000250|UniProtKB:P15209}. Early endosome membrane CC {ECO:0000250|UniProtKB:P15209}. Cell projection, axon CC {ECO:0000250|UniProtKB:Q63604}. Cell projection, dendrite CC {ECO:0000250|UniProtKB:Q63604}. Cytoplasm, perinuclear region CC {ECO:0000250|UniProtKB:Q63604}. Postsynaptic density CC {ECO:0000250|UniProtKB:P15209}. Note=Internalized to endosomes upon CC ligand-binding. {ECO:0000250|UniProtKB:P15209}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=7; CC Comment=Additional isoforms seem to exist.; CC Name=TrkB; Synonyms=gp145-TrkB; CC IsoId=Q16620-1; Sequence=Displayed; CC Name=TrkB-T1; CC IsoId=Q16620-2; Sequence=VSP_002901, VSP_002902; CC Name=TrkB-T-Shc; CC IsoId=Q16620-3; Sequence=VSP_002903, VSP_002904; CC Name=4; CC IsoId=Q16620-4; Sequence=VSP_041942; CC Name=5; CC IsoId=Q16620-5; Sequence=VSP_041942, VSP_002903, VSP_002904; CC Name=TrkB-T-TK; CC IsoId=Q16620-6; Sequence=VSP_042178, VSP_042179; CC Name=TrkB-N-T1; CC IsoId=Q16620-7; Sequence=VSP_042177, VSP_002901, VSP_002902; CC -!- TISSUE SPECIFICITY: Isoform TrkB is expressed in the central and CC peripheral nervous system. In the central nervous system (CNS), CC expression is observed in the cerebral cortex, hippocampus, thalamus, CC choroid plexus, granular layer of the cerebellum, brain stem, and CC spinal cord. In the peripheral nervous system, it is expressed in many CC cranial ganglia, the ophthalmic nerve, the vestibular system, multiple CC facial structures, the submaxillary glands, and dorsal root ganglia. CC Isoform TrkB-T1 is mainly expressed in the brain but also detected in CC other tissues including pancreas, kidney and heart. Isoform TrkB-T-Shc CC is predominantly expressed in the brain. {ECO:0000269|PubMed:11798182, CC ECO:0000269|PubMed:7936202}. CC -!- DEVELOPMENTAL STAGE: Widely expressed in fetal brain. CC {ECO:0000269|PubMed:7936202}. CC -!- PTM: Phosphorylated. Undergoes ligand-mediated autophosphorylation that CC is required for interaction with SHC1 and PLCG1 and other downstream CC effectors. Isoform TrkB-T-Shc is not phosphorylated. CC {ECO:0000269|PubMed:15494731}. CC -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation; CC regulated by NGFR. Ubiquitination regulates the internalization of the CC receptor (By similarity). {ECO:0000250}. CC -!- DISEASE: Developmental and epileptic encephalopathy 58 (DEE58) CC [MIM:617830]: A form of epileptic encephalopathy, a heterogeneous group CC of severe early-onset epilepsies characterized by refractory seizures, CC neurodevelopmental impairment, and poor prognosis. Development is CC normal prior to seizure onset, after which cognitive and motor delays CC become apparent. DEE58 is an autosomal dominant condition characterized CC by onset of refractory seizures in the first days or months of life. CC {ECO:0000269|PubMed:29100083}. Note=The disease may be caused by CC variants affecting the gene represented in this entry. CC -!- DISEASE: Obesity, hyperphagia, and developmental delay (OBHD) CC [MIM:613886]: A disorder characterized by early-onset obesity, CC hyperphagia, and severe developmental delay in motor function, speech, CC and language. {ECO:0000269|PubMed:15494731, CC ECO:0000269|PubMed:27884935, ECO:0000269|PubMed:29100083}. Note=The CC disease is caused by variants affecting the gene represented in this CC entry. CC -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase since the CC first Trk was isolated as an oncogenic protein which was the result of CC a fusion between the tropomyosin gene TPM3 and NTRK1. CC -!- MISCELLANEOUS: [Isoform TrkB-T1]: Non-catalytic isoform. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein CC kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/41589/NTRK2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U12140; AAC51371.1; -; mRNA. DR EMBL; S76473; AAB33109.1; -; mRNA. DR EMBL; S76474; AAB33110.1; -; mRNA. DR EMBL; X75958; CAA53571.1; -; mRNA. DR EMBL; AF410899; AAL67965.1; -; mRNA. DR EMBL; AF410900; AAL67966.1; -; mRNA. DR EMBL; AF410901; AAL67967.1; -; mRNA. DR EMBL; AF508964; AAM77876.1; -; mRNA. DR EMBL; AB209118; BAD92355.1; -; mRNA. DR EMBL; AK294285; BAG57570.1; -; mRNA. DR EMBL; AL390777; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL445532; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL596132; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; CH471089; EAW62688.1; -; Genomic_DNA. DR EMBL; BC031835; AAH31835.1; -; mRNA. DR CCDS; CCDS35050.1; -. [Q16620-1] DR CCDS; CCDS35051.1; -. [Q16620-5] DR CCDS; CCDS35052.1; -. [Q16620-3] DR CCDS; CCDS35053.1; -. [Q16620-2] DR CCDS; CCDS6671.1; -. [Q16620-4] DR CCDS; CCDS94429.1; -. [Q16620-7] DR PIR; A56853; A56853. DR PIR; I73631; I73631. DR RefSeq; NP_001007098.1; NM_001007097.3. [Q16620-2] DR RefSeq; NP_001018074.1; NM_001018064.3. [Q16620-1] DR RefSeq; NP_001018075.1; NM_001018065.2. [Q16620-5] DR RefSeq; NP_001018076.1; NM_001018066.3. [Q16620-3] DR RefSeq; NP_001356461.1; NM_001369532.1. [Q16620-1] DR RefSeq; NP_001356462.1; NM_001369533.1. [Q16620-1] DR RefSeq; NP_001356466.1; NM_001369537.1. [Q16620-5] DR RefSeq; NP_001356467.1; NM_001369538.1. [Q16620-3] DR RefSeq; NP_001356468.1; NM_001369539.1. [Q16620-2] DR RefSeq; NP_001356469.1; NM_001369540.1. [Q16620-2] DR RefSeq; NP_001356470.1; NM_001369541.1. [Q16620-2] DR RefSeq; NP_001356471.1; NM_001369542.1. [Q16620-2] DR RefSeq; NP_001356472.1; NM_001369543.1. [Q16620-2] DR RefSeq; NP_001356473.1; NM_001369544.1. [Q16620-2] DR RefSeq; NP_001356474.1; NM_001369545.1. [Q16620-2] DR RefSeq; NP_001356477.1; NM_001369548.1. [Q16620-2] DR RefSeq; NP_001356478.1; NM_001369549.1. [Q16620-2] DR RefSeq; NP_001356479.1; NM_001369550.1. [Q16620-7] DR RefSeq; NP_001356480.1; NM_001369551.1. [Q16620-7] DR RefSeq; NP_001356481.1; NM_001369552.1. [Q16620-7] DR RefSeq; NP_006171.2; NM_006180.4. [Q16620-4] DR RefSeq; XP_005252058.1; XM_005252001.4. [Q16620-4] DR RefSeq; XP_005252060.1; XM_005252003.4. [Q16620-4] DR RefSeq; XP_005252061.1; XM_005252004.3. [Q16620-4] DR RefSeq; XP_011517020.1; XM_011518718.4. [Q16620-1] DR RefSeq; XP_016870240.1; XM_017014751.3. [Q16620-4] DR RefSeq; XP_016870241.1; XM_017014752.2. [Q16620-1] DR RefSeq; XP_016870242.1; XM_017014753.3. [Q16620-1] DR RefSeq; XP_016870244.1; XM_017014755.1. [Q16620-5] DR RefSeq; XP_016870249.1; XM_017014760.3. [Q16620-2] DR RefSeq; XP_047279388.1; XM_047423432.1. [Q16620-4] DR RefSeq; XP_047279389.1; XM_047423433.1. [Q16620-4] DR RefSeq; XP_054218993.1; XM_054363018.1. [Q16620-4] DR RefSeq; XP_054218994.1; XM_054363019.1. [Q16620-4] DR RefSeq; XP_054218995.1; XM_054363020.1. [Q16620-4] DR RefSeq; XP_054218996.1; XM_054363021.1. [Q16620-4] DR RefSeq; XP_054218997.1; XM_054363022.1. [Q16620-4] DR RefSeq; XP_054218998.1; XM_054363023.1. [Q16620-4] DR RefSeq; XP_054218999.1; XM_054363024.1. [Q16620-1] DR RefSeq; XP_054219000.1; XM_054363025.1. [Q16620-1] DR RefSeq; XP_054219001.1; XM_054363026.1. [Q16620-1] DR RefSeq; XP_054219002.1; XM_054363027.1. [Q16620-5] DR RefSeq; XP_054219003.1; XM_054363028.1. [Q16620-2] DR PDB; 1HCF; X-ray; 2.70 A; X/Y=286-383. DR PDB; 1WWB; X-ray; 2.10 A; X=283-385. DR PDB; 2MFQ; NMR; -; B=497-519. DR PDB; 4ASZ; X-ray; 1.70 A; A=527-822. DR PDB; 4AT3; X-ray; 1.77 A; A=527-822. DR PDB; 4AT4; X-ray; 2.36 A; A=527-822. DR PDB; 4AT5; X-ray; 1.71 A; A=527-822. DR PDB; 5MO9; X-ray; 2.59 A; X=278-426. DR PDB; 8OYD; NMR; -; A/B=422-466. DR PDBsum; 1HCF; -. DR PDBsum; 1WWB; -. DR PDBsum; 2MFQ; -. DR PDBsum; 4ASZ; -. DR PDBsum; 4AT3; -. DR PDBsum; 4AT4; -. DR PDBsum; 4AT5; -. DR PDBsum; 5MO9; -. DR PDBsum; 8OYD; -. DR AlphaFoldDB; Q16620; -. DR SMR; Q16620; -. DR BioGRID; 110970; 137. DR DIP; DIP-5720N; -. DR FunCoup; Q16620; 1218. DR IntAct; Q16620; 116. DR MINT; Q16620; -. DR STRING; 9606.ENSP00000277120; -. DR BindingDB; Q16620; -. DR ChEMBL; CHEMBL4898; -. DR DrugBank; DB00321; Amitriptyline. DR DrugBank; DB11986; Entrectinib. DR DrugBank; DB11823; Esketamine. DR DrugBank; DB12010; Fostamatinib. DR DrugBank; DB16056; GZ-389988. DR DrugBank; DB14723; Larotrectinib. DR DrugBank; DB16826; Repotrectinib. DR DrugCentral; Q16620; -. DR GuidetoPHARMACOLOGY; 1818; -. DR TCDB; 8.A.23.1.38; the basigin (basigin) family. DR GlyConnect; 1029; 12 N-Linked glycans (7 sites). DR GlyCosmos; Q16620; 13 sites, 14 glycans. DR GlyGen; Q16620; 13 sites, 21 N-linked glycans (8 sites), 1 O-linked glycan (1 site). DR iPTMnet; Q16620; -. DR PhosphoSitePlus; Q16620; -. DR SwissPalm; Q16620; -. DR BioMuta; NTRK2; -. DR DMDM; 2497560; -. DR jPOST; Q16620; -. DR MassIVE; Q16620; -. DR PaxDb; 9606-ENSP00000277120; -. DR PeptideAtlas; Q16620; -. DR ProteomicsDB; 60955; -. [Q16620-1] DR ProteomicsDB; 60956; -. [Q16620-2] DR ProteomicsDB; 60957; -. [Q16620-3] DR ProteomicsDB; 60958; -. [Q16620-4] DR ProteomicsDB; 60959; -. [Q16620-5] DR ProteomicsDB; 60960; -. [Q16620-6] DR ProteomicsDB; 60961; -. [Q16620-7] DR ABCD; Q16620; 146 sequenced antibodies. DR Antibodypedia; 2081; 1498 antibodies from 49 providers. DR DNASU; 4915; -. DR Ensembl; ENST00000277120.8; ENSP00000277120.3; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000304053.11; ENSP00000306167.7; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000359847.4; ENSP00000352906.3; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000376208.6; ENSP00000365381.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000376213.6; ENSP00000365386.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000395882.6; ENSP00000379221.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000685720.1; ENSP00000509031.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000686259.1; ENSP00000509743.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000686322.1; ENSP00000510032.1; ENSG00000148053.19. [Q16620-7] DR Ensembl; ENST00000686324.1; ENSP00000510134.1; ENSG00000148053.19. [Q16620-4] DR Ensembl; ENST00000686443.1; ENSP00000509093.1; ENSG00000148053.19. [Q16620-3] DR Ensembl; ENST00000686496.1; ENSP00000510060.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000687148.1; ENSP00000510717.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687596.1; ENSP00000509999.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000687636.1; ENSP00000508829.1; ENSG00000148053.19. [Q16620-5] DR Ensembl; ENST00000688013.1; ENSP00000508443.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689685.1; ENSP00000509169.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000689815.1; ENSP00000510451.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000690281.1; ENSP00000510757.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691415.1; ENSP00000509058.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000691788.1; ENSP00000509401.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692181.1; ENSP00000510619.1; ENSG00000148053.19. [Q16620-1] DR Ensembl; ENST00000692389.1; ENSP00000508497.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692506.1; ENSP00000508622.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000692762.1; ENSP00000510071.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693109.1; ENSP00000509456.1; ENSG00000148053.19. [Q16620-2] DR Ensembl; ENST00000693539.1; ENSP00000510640.1; ENSG00000148053.19. [Q16620-5] DR GeneID; 4915; -. DR KEGG; hsa:4915; -. DR MANE-Select; ENST00000277120.8; ENSP00000277120.3; NM_006180.6; NP_006171.2. [Q16620-4] DR UCSC; uc004anz.1; human. [Q16620-1] DR AGR; HGNC:8032; -. DR CIViC; 4915; 5 evidence items across 2 molecular profiles. DR ClinPGx; PA31818; -. DR CTD; 4915; -. DR DisGeNET; 4915; -. DR GeneCards; NTRK2; -. DR HGNC; HGNC:8032; NTRK2. DR HPA; ENSG00000148053; Tissue enhanced (brain, thyroid gland). DR MalaCards; NTRK2; -. DR MIM; 600456; gene. DR MIM; 613886; phenotype. DR MIM; 617830; phenotype. DR OpenTargets; ENSG00000148053; -. DR Orphanet; 99704; Early-onset obesity-hyperphagia-severe developmental delay syndrome. DR Orphanet; 697160; Infantile epileptic spasms syndrome. DR Orphanet; 442835; Non-specific early-onset epileptic encephalopathy. DR Orphanet; 251615; Pilomyxoid astrocytoma. DR VEuPathDB; HostDB:ENSG00000148053; -. DR eggNOG; KOG1026; Eukaryota. DR GeneTree; ENSGT00940000155181; -. DR HOGENOM; CLU_000288_74_1_1; -. DR InParanoid; Q16620; -. DR OMA; HIAMQIA; -. DR OrthoDB; 10005095at2759; -. DR PAN-GO; Q16620; 16 GO annotations based on evolutionary models. DR PhylomeDB; Q16620; -. DR BRENDA; 2.7.10.1; 2681. DR PathwayCommons; Q16620; -. DR Reactome; R-HSA-1257604; PIP3 activates AKT signaling. DR Reactome; R-HSA-187024; NGF-independant TRKA activation. DR Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer. DR Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling. DR Reactome; R-HSA-9024909; BDNF activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9025046; NTF3 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026357; NTF4 activates NTRK2 (TRKB) signaling. DR Reactome; R-HSA-9026519; Activated NTRK2 signals through RAS. DR Reactome; R-HSA-9026527; Activated NTRK2 signals through PLCG1. DR Reactome; R-HSA-9028335; Activated NTRK2 signals through PI3K. DR Reactome; R-HSA-9028731; Activated NTRK2 signals through FRS2 and FRS3. DR Reactome; R-HSA-9032500; Activated NTRK2 signals through FYN. DR Reactome; R-HSA-9032759; NTRK2 activates RAC1. DR Reactome; R-HSA-9032845; Activated NTRK2 signals through CDK5. DR SignaLink; Q16620; -. DR SIGNOR; Q16620; -. DR Agora; ENSG00000148053; Agora Nominated Target for Alzheimer's Disease. DR BioGRID-ORCS; 4915; 10 hits in 1188 CRISPR screens. DR ChiTaRS; NTRK2; human. DR EvolutionaryTrace; Q16620; -. DR GeneWiki; TrkB_receptor; -. DR GenomeRNAi; 4915; -. DR Pharos; Q16620; Tclin. DR PRO; PR:Q16620; -. DR Proteomes; UP000005640; Chromosome 9. DR RNAct; Q16620; protein. DR Bgee; ENSG00000148053; Expressed in cranial nerve II and 196 other cell types or tissues. DR ExpressionAtlas; Q16620; baseline and differential. DR GO; GO:0030424; C:axon; ISS:UniProtKB. DR GO; GO:0043679; C:axon terminus; IBA:GO_Central. DR GO; GO:0005829; C:cytosol; IEA:Ensembl. DR GO; GO:0030425; C:dendrite; ISS:UniProtKB. DR GO; GO:0043197; C:dendritic spine; IBA:GO_Central. DR GO; GO:0005769; C:early endosome; ISS:UniProtKB. DR GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell. DR GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB. DR GO; GO:0005886; C:plasma membrane; IDA:HPA. DR GO; GO:0014069; C:postsynaptic density; ISS:ARUK-UCL. DR GO; GO:0043235; C:receptor complex; IDA:MGI. DR GO; GO:0043195; C:terminal bouton; IEA:Ensembl. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0048403; F:brain-derived neurotrophic factor binding; ISS:UniProtKB. DR GO; GO:0060175; F:brain-derived neurotrophic factor receptor activity; IMP:UniProtKB. DR GO; GO:0043121; F:neurotrophin binding; IDA:UniProtKB. DR GO; GO:0002020; F:protease binding; IPI:ARUK-UCL. DR GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB. DR GO; GO:0031547; P:brain-derived neurotrophic factor receptor signaling pathway; IMP:UniProtKB. DR GO; GO:0007169; P:cell surface receptor protein tyrosine kinase signaling pathway; IBA:GO_Central. DR GO; GO:0071230; P:cellular response to amino acid stimulus; IEA:Ensembl. DR GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IBA:GO_Central. DR GO; GO:0021954; P:central nervous system neuron development; ISS:UniProtKB. DR GO; GO:0021987; P:cerebral cortex development; ISS:UniProtKB. DR GO; GO:0007623; P:circadian rhythm; IEA:Ensembl. DR GO; GO:0007631; P:feeding behavior; IEA:Ensembl. DR GO; GO:0014047; P:glutamate secretion; IEA:Ensembl. DR GO; GO:0007612; P:learning; ISS:UniProtKB. DR GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl. DR GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl. DR GO; GO:0022011; P:myelination in peripheral nervous system; IEA:Ensembl. DR GO; GO:1902430; P:negative regulation of amyloid-beta formation; IGI:ARUK-UCL. DR GO; GO:2000811; P:negative regulation of anoikis; IEA:Ensembl. DR GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB. DR GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB. DR GO; GO:0001764; P:neuron migration; ISS:UniProtKB. DR GO; GO:0019227; P:neuronal action potential propagation; IEA:Ensembl. DR GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0048935; P:peripheral nervous system neuron development; IEA:Ensembl. DR GO; GO:0050772; P:positive regulation of axonogenesis; ISS:UniProtKB. DR GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB. DR GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB. DR GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB. DR GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISS:UniProtKB. DR GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl. DR GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB. DR GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0046548; P:retinal rod cell development; IEA:Ensembl. DR GO; GO:0099183; P:trans-synaptic signaling by BDNF, modulating synaptic transmission; IEA:Ensembl. DR GO; GO:0001570; P:vasculogenesis; IEA:Ensembl. DR CDD; cd05855; IgI_TrkB_d5; 1. DR CDD; cd05093; PTKc_TrkB; 1. DR DisProt; DP03945; -. DR FunFam; 2.60.40.10:FF:000239; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 3.80.10.10:FF:000048; BDNF/NT-3 growth factors receptor; 1. DR FunFam; 1.10.510.10:FF:000034; Tyrosine-protein kinase receptor; 1. DR FunFam; 2.60.40.10:FF:000486; Tyrosine-protein kinase receptor; 1. DR FunFam; 3.30.200.20:FF:000033; Tyrosine-protein kinase receptor; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 2. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR IDEAL; IID00672; -. DR InterPro; IPR000483; Cys-rich_flank_reg_C. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR013098; Ig_I-set. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR003598; Ig_sub2. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR001611; Leu-rich_rpt. DR InterPro; IPR032675; LRR_dom_sf. DR InterPro; IPR000372; LRRNT. DR InterPro; IPR020777; NTRK. DR InterPro; IPR020455; NTRK2. DR InterPro; IPR031635; NTRK_LRRCT. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR050122; RTK. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR InterPro; IPR020635; Tyr_kinase_cat_dom. DR InterPro; IPR002011; Tyr_kinase_rcpt_2_CS. DR PANTHER; PTHR24416:SF136; BDNF_NT-3 GROWTH FACTORS RECEPTOR; 1. DR PANTHER; PTHR24416; TYROSINE-PROTEIN KINASE RECEPTOR; 1. DR Pfam; PF07679; I-set; 2. DR Pfam; PF13855; LRR_8; 1. DR Pfam; PF16920; LRRCT_2; 1. DR Pfam; PF01462; LRRNT; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR PRINTS; PR01939; NTKRECEPTOR. DR PRINTS; PR01941; NTKRECEPTOR2. DR PRINTS; PR00109; TYRKINASE. DR SMART; SM00409; IG; 1. DR SMART; SM00408; IGc2; 1. DR SMART; SM00082; LRRCT; 1. DR SMART; SM00013; LRRNT; 1. DR SMART; SM00219; TyrKc; 1. DR SUPFAM; SSF48726; Immunoglobulin; 2. DR SUPFAM; SSF52058; L domain-like; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; ATP-binding; Cell membrane; KW Cell projection; Cytoplasm; Developmental protein; Differentiation; KW Disease variant; Disulfide bond; Endosome; Epilepsy; Glycoprotein; KW Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis; KW Nucleotide-binding; Obesity; Phosphoprotein; Proteomics identification; KW Receptor; Reference proteome; Repeat; Signal; Synapse; Transferase; KW Transmembrane; Transmembrane helix; Tyrosine-protein kinase; KW Ubl conjugation. FT SIGNAL 1..31 FT CHAIN 32..822 FT /note="BDNF/NT-3 growth factors receptor" FT /id="PRO_0000016727" FT TOPO_DOM 32..430 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 431..454 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 455..822 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 32..61 FT /note="LRRNT" FT REPEAT 92..113 FT /note="LRR 1" FT REPEAT 116..137 FT /note="LRR 2" FT DOMAIN 148..196 FT /note="LRRCT" FT DOMAIN 197..282 FT /note="Ig-like C2-type 1" FT DOMAIN 295..365 FT /note="Ig-like C2-type 2" FT DOMAIN 538..807 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 455..466 FT /note="Interaction with MAPK8IP3/JIP3" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT REGION 475..498 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 485..495 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 676 FT /note="Proton acceptor" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159, FT ECO:0000255|PROSITE-ProRule:PRU10028" FT BINDING 544..552 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 572 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT SITE 516 FT /note="Interaction with SHC1" FT /evidence="ECO:0000250" FT SITE 706 FT /note="Interaction with SH2D1A" FT /evidence="ECO:0000250" FT SITE 817 FT /note="Interaction with PLCG1" FT /evidence="ECO:0000250" FT MOD_RES 516 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:P15209" FT MOD_RES 702 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 706 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 707 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT MOD_RES 817 FT /note="Phosphotyrosine; by autocatalysis" FT /evidence="ECO:0000250|UniProtKB:Q63604" FT CARBOHYD 67 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 95 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 121 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 178 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 205 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 241 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 254 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:16335952, FT ECO:0000269|PubMed:7574684" FT CARBOHYD 280 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 325 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 338 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT CARBOHYD 412 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000269|PubMed:7574684" FT DISULFID 32..38 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 36..45 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 152..176 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 154..194 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 218..266 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:7574684" FT DISULFID 302..345 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00114, FT ECO:0000269|PubMed:10388563, ECO:0000269|PubMed:11738045, FT ECO:0000269|PubMed:7574684, ECO:0007744|PDB:1HCF, FT ECO:0007744|PDB:1WWB, ECO:0007744|PDB:5MO9" FT VAR_SEQ 1..156 FT /note="Missing (in isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_042177" FT VAR_SEQ 465 FT /note="K -> KDFSWFGFGKVKSRQGV (in isoform 4 and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_041942" FT VAR_SEQ 467..477 FT /note="PASVISNDDDS -> FVLFHKIPLDG (in isoform TrkB-T1 and FT isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002901" FT VAR_SEQ 478..822 FT /note="Missing (in isoform TrkB-T1 and isoform TrkB-N-T1)" FT /evidence="ECO:0000303|PubMed:11798182, FT ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:15489334, FT ECO:0000303|PubMed:7823156, ECO:0000303|PubMed:7936202, FT ECO:0000303|Ref.5" FT /id="VSP_002902" FT VAR_SEQ 529..537 FT /note="FVQHIKRHN -> WPRGSPKTA (in isoform TrkB-T-Shc and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002903" FT VAR_SEQ 538..822 FT /note="Missing (in isoform TrkB-T-Shc and isoform 5)" FT /evidence="ECO:0000303|PubMed:11798182" FT /id="VSP_002904" FT VAR_SEQ 710..735 FT /note="GGHTMLPIRWMPPESIMYRKFTTESD -> SSCADQRPQGPLSLRDPCCICL FT LRLS (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042178" FT VAR_SEQ 736..822 FT /note="Missing (in isoform TrkB-T-TK)" FT /evidence="ECO:0000303|Ref.7" FT /id="VSP_042179" FT VARIANT 138 FT /note="L -> F (in a lung adenocarcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041470" FT VARIANT 309 FT /note="G -> R" FT /evidence="ECO:0000269|Ref.5" FT /id="VAR_016320" FT VARIANT 338 FT /note="N -> Y (in dbSNP:rs1047856)" FT /id="VAR_011973" FT VARIANT 434 FT /note="Y -> C (in DEE58; uncertain significance; FT dbSNP:rs886041091)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080659" FT VARIANT 444..822 FT /note="Missing (in OBHD)" FT /evidence="ECO:0000269|PubMed:27884935" FT /id="VAR_080660" FT VARIANT 545 FT /note="G -> V (in dbSNP:rs1075108)" FT /id="VAR_049715" FT VARIANT 697 FT /note="M -> I (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046518" FT VARIANT 699 FT /note="R -> G (in a lung carcinoma sample; somatic FT mutation)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046519" FT VARIANT 704 FT /note="T -> I (in OBHD; uncertain significance; FT dbSNP:rs1554774973)" FT /evidence="ECO:0000269|PubMed:29100083" FT /id="VAR_080661" FT VARIANT 706 FT /note="Y -> C (in OBHD; expressed normally on the cell FT surface; results in markedly impaired ligand-induced FT phosphorylation as well as impaired downstream MAPK1 FT phosphorylation; dbSNP:rs121434633)" FT /evidence="ECO:0000269|PubMed:15494731" FT /id="VAR_065890" FT VARIANT 718 FT /note="R -> C (in a lung carcinoma sample; somatic FT mutation; dbSNP:rs1324578301)" FT /evidence="ECO:0000269|PubMed:18293376" FT /id="VAR_046520" FT STRAND 285..292 FT /evidence="ECO:0007829|PDB:5MO9" FT STRAND 300..308 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 314..319 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 322..324 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 328..337 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 339..350 FT /evidence="ECO:0007829|PDB:1WWB" FT HELIX 353..355 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 357..364 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 369..376 FT /evidence="ECO:0007829|PDB:1WWB" FT STRAND 380..382 FT /evidence="ECO:0007829|PDB:5MO9" FT HELIX 428..460 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 462..464 FT /evidence="ECO:0007829|PDB:8OYD" FT STRAND 500..503 FT /evidence="ECO:0007829|PDB:2MFQ" FT STRAND 506..512 FT /evidence="ECO:0007829|PDB:2MFQ" FT TURN 515..517 FT /evidence="ECO:0007829|PDB:2MFQ" FT HELIX 535..537 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 538..545 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 552..557 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 567..574 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 579..592 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 603..607 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 609..618 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 625..631 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 634..638 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 641..643 FT /evidence="ECO:0007829|PDB:4AT5" FT HELIX 650..669 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 679..681 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 682..684 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 686..688 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 690..692 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 698..701 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 703..705 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 707..709 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 710..712 FT /evidence="ECO:0007829|PDB:4ASZ" FT STRAND 713..715 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 717..719 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 722..727 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 732..747 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 748..750 FT /evidence="ECO:0007829|PDB:4ASZ" FT TURN 753..756 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 759..768 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 780..789 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 794..796 FT /evidence="ECO:0007829|PDB:4ASZ" FT HELIX 800..813 FT /evidence="ECO:0007829|PDB:4ASZ" SQ SEQUENCE 822 AA; 91999 MW; 2FEB9159948F0D13 CRC64; MSSWIRWHGP AMARLWGFCW LVVGFWRAAF ACPTSCKCSA SRIWCSDPSP GIVAFPRLEP NSVDPENITE IFIANQKRLE IINEDDVEAY VGLRNLTIVD SGLKFVAHKA FLKNSNLQHI NFTRNKLTSL SRKHFRHLDL SELILVGNPF TCSCDIMWIK TLQEAKSSPD TQDLYCLNES SKNIPLANLQ IPNCGLPSAN LAAPNLTVEE GKSITLSCSV AGDPVPNMYW DVGNLVSKHM NETSHTQGSL RITNISSDDS GKQISCVAEN LVGEDQDSVN LTVHFAPTIT FLESPTSDHH WCIPFTVKGN PKPALQWFYN GAILNESKYI CTKIHVTNHT EYHGCLQLDN PTHMNNGDYT LIAKNEYGKD EKQISAHFMG WPGIDDGANP NYPDVIYEDY GTAANDIGDT TNRSNEIPST DVTDKTGREH LSVYAVVVIA SVVGFCLLVM LFLLKLARHS KFGMKGPASV ISNDDDSASP LHHISNGSNT PSSSEGGPDA VIIGMTKIPV IENPQYFGIT NSQLKPDTFV QHIKRHNIVL KRELGEGAFG KVFLAECYNL CPEQDKILVA VKTLKDASDN ARKDFHREAE LLTNLQHEHI VKFYGVCVEG DPLIMVFEYM KHGDLNKFLR AHGPDAVLMA EGNPPTELTQ SQMLHIAQQI AAGMVYLASQ HFVHRDLATR NCLVGENLLV KIGDFGMSRD VYSTDYYRVG GHTMLPIRWM PPESIMYRKF TTESDVWSLG VVLWEIFTYG KQPWYQLSNN EVIECITQGR VLQRPRTCPQ EVYELMLGCW QREPHMRKNI KGIHTLLQNL AKASPVYLDI LG // ID TBK1_HUMAN Reviewed; 729 AA. AC Q9UHD2; A8K4S4; Q8IYV3; Q9NUJ5; DT 20-DEC-2005, integrated into UniProtKB/Swiss-Prot. DT 01-MAY-2000, sequence version 1. DT 28-JAN-2026, entry version 215. DE RecName: Full=Serine/threonine-protein kinase TBK1 {ECO:0000305}; DE EC=2.7.11.1 {ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, ECO:0000269|PubMed:25636800}; DE AltName: Full=NF-kappa-B-activating kinase {ECO:0000303|PubMed:10783893}; DE AltName: Full=T2K; DE AltName: Full=TANK-binding kinase 1 {ECO:0000303|PubMed:10581243}; GN Name=TBK1 {ECO:0000303|PubMed:10581243, ECO:0000312|HGNC:HGNC:11584}; GN Synonyms=NAK {ECO:0000303|PubMed:10783893}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH TANK AND TRAF2, AND RP MUTAGENESIS OF LYS-38. RC TISSUE=Spleen; RX PubMed=10581243; DOI=10.1093/emboj/18.23.6694; RA Pomerantz J.L., Baltimore D.; RT "NF-kB activation by a signaling complex containing TRAF2, TANK, and TBK1, RT a novel IKK-related kinase."; RL EMBO J. 18:6694-6704(1999). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN PHOSPHORYLATION OF NFKBIA AND RP IKBKB, TISSUE SPECIFICITY, AND CATALYTIC ACTIVITY. RX PubMed=10783893; DOI=10.1038/35008109; RA Tojima Y., Fujimoto A., Delhase M., Chen Y., Hatakeyama S., Nakayama K., RA Kaneko Y., Nimura Y., Motoyama N., Ikeda K., Karin M., Nakanishi M.; RT "NAK is an IkappaB kinase-activating kinase."; RL Nature 404:778-782(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Placenta; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASP-388 AND GLN-570. RC TISSUE=Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP FUNCTION, MUTAGENESIS OF SER-172, AND PHOSPHORYLATION AT SER-172. RX PubMed=11839743; DOI=10.1074/jbc.m110474200; RA Kishore N., Huynh Q.K., Mathialagan S., Hall T., Rouw S., Creely D., RA Lange G., Caroll J., Reitz B., Donnelly A., Boddupalli H., Combs R.G., RA Kretzmer K., Tripp C.S.; RT "IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK- RT 2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2."; RL J. Biol. Chem. 277:13840-13847(2002). RN [7] RP INTERACTION WITH TIRAP AND TICAM1. RX PubMed=14530355; DOI=10.4049/jimmunol.171.8.4304; RA Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., RA Akira S.; RT "Toll/IL-1 receptor domain-containing adapter inducing IFN-beta (TRIF) RT associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, RT and activates two distinct transcription factors, NF-kappa B and IFN- RT regulatory factor-3, in the Toll-like receptor signaling."; RL J. Immunol. 171:4304-4310(2003). RN [8] RP FUNCTION. RX PubMed=12692549; DOI=10.1038/ni921; RA Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., RA Golenbock D.T., Coyle A.J., Liao S.-M., Maniatis T.; RT "IKKepsilon and TBK1 are essential components of the IRF3 signaling RT pathway."; RL Nat. Immunol. 4:491-496(2003). RN [9] RP FUNCTION. RX PubMed=12702806; DOI=10.1126/science.1081315; RA Sharma S., tenOever B.R., Grandvaux N., Zhou G.-P., Lin R., Hiscott J.; RT "Triggering the interferon antiviral response through an IKK-related RT pathway."; RL Science 300:1148-1151(2003). RN [10] RP INTERACTION WITH AZI2. RX PubMed=14560022; DOI=10.1128/mcb.23.21.7780-7793.2003; RA Fujita F., Taniguchi Y., Kato T., Narita Y., Furuya A., Ogawa T., RA Sakurai H., Joh T., Itoh M., Delhase M., Karin M., Nakanishi M.; RT "Identification of NAP1, a regulatory subunit of IkappaB kinase-related RT kinases that potentiates NF-kappaB signaling."; RL Mol. Cell. Biol. 23:7780-7793(2003). RN [11] RP FUNCTION IN PHOSPHORYLATION OF IRF3, AND CATALYTIC ACTIVITY. RX PubMed=14703513; DOI=10.1074/jbc.m310616200; RA Mori M., Yoneyama M., Ito T., Takahashi K., Inagaki F., Fujita T.; RT "Identification of Ser-386 of interferon regulatory factor 3 as critical RT target for inducible phosphorylation that determines activation."; RL J. Biol. Chem. 279:9698-9702(2004). RN [12] RP INTERACTION WITH TICAM1. RX PubMed=14739303; DOI=10.1074/jbc.m311629200; RA Han K.J., Su X., Xu L.-G., Bin L.H., Zhang J., Shu H.-B.; RT "Mechanisms of the TRIF-induced interferon-stimulated response element and RT NF-kappaB activation and apoptosis pathways."; RL J. Biol. Chem. 279:15652-15661(2004). RN [13] RP FUNCTION, AND SUBCELLULAR LOCATION. RX PubMed=15485837; DOI=10.1074/jbc.m411037200; RA Kuai J., Wooters J., Hall J.P., Rao V.R., Nickbarg E., Li B., RA Chatterjee-Kishore M., Qiu Y., Lin L.-L.; RT "NAK is recruited to the TNFR1 complex in a TNFalpha-dependent manner and RT mediates the production of RANTES: identification of endogenous TNFR- RT interacting proteins by a proteomic approach."; RL J. Biol. Chem. 279:53266-53271(2004). RN [14] RP FUNCTION IN PHOSPHORYLATION OF RELA, AND CATALYTIC ACTIVITY. RX PubMed=15489227; DOI=10.1074/jbc.m409825200; RA Buss H., Dorrie A., Schmitz M.L., Hoffmann E., Resch K., Kracht M.; RT "Constitutive and interleukin-1-inducible phosphorylation of p65 RT NF-{kappa}B at serine 536 is mediated by multiple protein kinases including RT I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family RT member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and RT couples p65 to TATA-binding protein-associated factor II31-mediated RT interleukin-8 transcription."; RL J. Biol. Chem. 279:55633-55643(2004). RN [15] RP FUNCTION IN PHOSPHORYLATION OF IRF7, AND CATALYTIC ACTIVITY. RX PubMed=15367631; DOI=10.1128/jvi.78.19.10636-10649.2004; RA tenOever B.R., Sharma S., Zou W., Sun Q., Grandvaux N., Julkunen I., RA Hemmi H., Yamamoto M., Akira S., Yeh W.C., Lin R., Hiscott J.; RT "Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus RT infection and the role of viral ribonucleoprotein in the development of RT interferon antiviral immunity."; RL J. Virol. 78:10636-10649(2004). RN [16] RP INTERACTION WITH SIKE1; IRF3; TICAM1 AND RIGI. RX PubMed=16281057; DOI=10.1038/sj.emboj.7600863; RA Huang J., Liu T., Xu L.-G., Chen D., Zhai Z., Shu H.-B.; RT "SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus- RT triggered IRF-3 activation pathways."; RL EMBO J. 24:4018-4028(2005). RN [17] RP INTERACTION WITH HCV NS3 (MICROBIAL INFECTION). RX PubMed=15841462; DOI=10.1002/hep.20666; RA Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., RA Kawabe T., Omata M.; RT "Interaction between the HCV NS3 protein and the host TBK1 protein leads to RT inhibition of cellular antiviral responses."; RL Hepatology 41:1004-1012(2005). RN [18] RP FUNCTION, AND INTERACTION WITH BORNA DISEASE VIRUS P PROTEIN. RX PubMed=16155125; DOI=10.1073/pnas.0502883102; RA Unterstab G., Ludwig S., Anton A., Planz O., Dauber B., Krappmann D., RA Heins G., Ehrhardt C., Wolff T.; RT "Viral targeting of the interferon-beta-inducing Traf family member- RT associated NF-kappa-B activator (TANK)-binding kinase-1."; RL Proc. Natl. Acad. Sci. U.S.A. 102:13640-13645(2005). RN [19] RP INTERACTION WITH EXOC2, AND SUBCELLULAR LOCATION. RX PubMed=17018283; DOI=10.1016/j.cell.2006.08.034; RA Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L., RA Balakireva M.G., Romeo Y., Kopelovich L., Gale M. Jr., Yeaman C., RA Camonis J.H., Zhao Y., White M.A.; RT "RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples RT innate immune signaling to tumor cell survival."; RL Cell 127:157-170(2006). RN [20] RP DOMAIN. RX PubMed=17599067; DOI=10.1038/sj.emboj.7601773; RA Ikeda F., Hecker C.M., Rozenknop A., Nordmeier R.D., Rogov V., Hofmann K., RA Akira S., Dotsch V., Dikic I.; RT "Involvement of the ubiquitin-like domain of TBK1/IKK-i kinases in RT regulation of IFN-inducible genes."; RL EMBO J. 26:3451-3462(2007). RN [21] RP FUNCTION IN PHOSPHORYLATION OF DDX3X, AND CATALYTIC ACTIVITY. RX PubMed=18583960; DOI=10.1038/emboj.2008.126; RA Soulat D., Burckstummer T., Westermayer S., Goncalves A., Bauch A., RA Stefanovic A., Hantschel O., Bennett K.L., Decker T., Superti-Furga G.; RT "The DEAD-box helicase DDX3X is a critical component of the TANK-binding RT kinase 1-dependent innate immune response."; RL EMBO J. 27:2135-2146(2008). RN [22] RP INTERACTION WITH CYLD. RX PubMed=18636086; DOI=10.1038/embor.2008.136; RA Friedman C.S., O'Donnell M.A., Legarda-Addison D., Ng A., Cardenas W.B., RA Yount J.S., Moran T.M., Basler C.F., Komuro A., Horvath C.M., Xavier R., RA Ting A.T.; RT "The tumour suppressor CYLD is a negative regulator of RIG-I-mediated RT antiviral response."; RL EMBO Rep. 9:930-936(2008). RN [23] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007; RA Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R., RA Greff Z., Keri G., Stemmann O., Mann M.; RT "Kinase-selective enrichment enables quantitative phosphoproteomics of the RT kinome across the cell cycle."; RL Mol. Cell 31:438-448(2008). RN [24] RP INTERACTION WITH SRC. RX PubMed=19419966; DOI=10.1074/jbc.m808233200; RA Johnsen I.B., Nguyen T.T., Bergstroem B., Fitzgerald K.A., Anthonsen M.W.; RT "The tyrosine kinase c-Src enhances RIG-I (retinoic acid-inducible gene I)- RT elicited antiviral signaling."; RL J. Biol. Chem. 284:19122-19131(2009). RN [25] RP INTERACTION WITH EBOLAVIRUS PROTEIN VP35, AND AUTOPHOSPHORYLATION. RX PubMed=19153231; DOI=10.1128/jvi.01875-08; RA Prins K.C., Cardenas W.B., Basler C.F.; RT "Ebola virus protein VP35 impairs the function of interferon regulatory RT factor-activating kinases IKKepsilon and TBK-1."; RL J. Virol. 83:3069-3077(2009). RN [26] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200; RA Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G., RA Mann M., Daub H.; RT "Large-scale proteomics analysis of the human kinome."; RL Mol. Cell. Proteomics 8:1751-1764(2009). RN [27] RP UBIQUITINATION BY NRDP1. RX PubMed=19483718; DOI=10.1038/ni.1742; RA Wang C., Chen T., Zhang J., Yang M., Li N., Xu X., Cao X.; RT "The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated RT production of type I interferon."; RL Nat. Immunol. 10:744-752(2009). RN [28] RP INTERACTION WITH STING1. RX PubMed=19416887; DOI=10.1073/pnas.0900818106; RA Li Y., Li C., Xue P., Zhong B., Mao A.P., Ran Y., Chen H., Wang Y.Y., RA Yang F., Shu H.B.; RT "ISG56 is a negative-feedback regulator of virus-triggered signaling and RT cellular antiviral response."; RL Proc. Natl. Acad. Sci. U.S.A. 106:7945-7950(2009). RN [29] RP INTERACTION WITH HSP90AA1. RX PubMed=20628368; DOI=10.1038/cr.2010.103; RA Liu X.Y., Wei B., Shi H.X., Shan Y.F., Wang C.; RT "Tom70 mediates activation of interferon regulatory factor 3 on RT mitochondria."; RL Cell Res. 20:994-1011(2010). RN [30] RP AUTOPHOSPHORYLATION, SUBUNIT, AND INTERACTION WITH GSK3B. RX PubMed=21145761; DOI=10.1016/j.immuni.2010.11.021; RA Lei C.Q., Zhong B., Zhang Y., Zhang J., Wang S., Shu H.B.; RT "Glycogen synthase kinase 3beta regulates IRF3 transcription factor- RT mediated antiviral response via activation of the kinase TBK1."; RL Immunity 33:878-889(2010). RN [31] RP INTERACTION WITH DDX3X. RX PubMed=20375222; DOI=10.1099/vir.0.020552-0; RA Yu S., Chen J., Wu M., Chen H., Kato N., Yuan Z.; RT "Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3- RT mediated beta interferon induction in human hepatocytes through RT interference with interferon regulatory factor 3 activation and dampening RT of the interaction between TBK1/IKKepsilon and DDX3."; RL J. Gen. Virol. 91:2080-2090(2010). RN [32] RP INTERACTION WITH OPTN AND TRAF3. RX PubMed=20174559; DOI=10.1371/journal.ppat.1000778; RA Mankouri J., Fragkoudis R., Richards K.H., Wetherill L.F., Harris M., RA Kohl A., Elliott R.M., Macdonald A.; RT "Optineurin negatively regulates the induction of IFNbeta in response to RT RNA virus infection."; RL PLoS Pathog. 6:E1000778-E1000778(2010). RN [33] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [34] RP INVOLVEMENT IN GLC1P, TISSUE SPECIFICITY, AND VARIANTS PHE-151; ILE-306 AND RP ALA-464. RX PubMed=21447600; DOI=10.1093/hmg/ddr123; RA Fingert J.H., Robin A.L., Stone J.L., Roos B.R., Davis L.K., Scheetz T.E., RA Bennett S.R., Wassink T.H., Kwon Y.H., Alward W.L., Mullins R.F., RA Sheffield V.C., Stone E.M.; RT "Copy number variations on chromosome 12q14 in patients with normal tension RT glaucoma."; RL Hum. Mol. Genet. 20:2482-2494(2011). RN [35] RP UBIQUITINATION BY MIB1. RX PubMed=21903422; DOI=10.1016/j.immuni.2011.06.014; RA Li S., Wang L., Berman M., Kong Y.Y., Dorf M.E.; RT "Mapping a dynamic innate immunity protein interaction network regulating RT type I interferon production."; RL Immunity 35:426-440(2011). RN [36] RP SUBCELLULAR LOCATION, AND INTERACTION WITH IFIT3 AND MAVS. RX PubMed=21813773; DOI=10.4049/jimmunol.1100963; RA Liu X.Y., Chen W., Wei B., Shan Y.F., Wang C.; RT "IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging RT MAVS and TBK1."; RL J. Immunol. 187:2559-2568(2011). RN [37] RP FUNCTION IN PHOSPHORYLATION OF VPS37C, AND CATALYTIC ACTIVITY. RX PubMed=21270402; DOI=10.4049/jimmunol.1000262; RA Da Q., Yang X., Xu Y., Gao G., Cheng G., Tang H.; RT "TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through RT targeting endosomal sorting complex required for transport-I."; RL J. Immunol. 186:3023-3030(2011). RN [38] RP FUNCTION, INTERACTION WITH AZI2; TANK AND TBKBP1, AND MUTAGENESIS OF RP ASP-135; MET-690; LEU-693; LYS-694; LEU-704; ASN-708 AND LEU-711. RX PubMed=21931631; DOI=10.1371/journal.pone.0023971; RA Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W., RA Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R., Planyavsky M., RA Bennett K.L., Colinge J., Superti-Furga G.; RT "Functional dissection of the TBK1 molecular network."; RL PLoS ONE 6:E23971-E23971(2011). RN [39] RP FUNCTION IN PHOSPHORYLATION OF AKT1, AND CATALYTIC ACTIVITY. RX PubMed=21464307; DOI=10.1073/pnas.1016132108; RA Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., RA Guan K.L.; RT "IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct RT phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 108:6474-6479(2011). RN [40] RP FUNCTION IN PHOSPHORYLATION OF OPTN, AND CATALYTIC ACTIVITY. RX PubMed=21617041; DOI=10.1126/science.1205405; RA Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., RA Richter B., Korac J., Waidmann O., Choudhary C., Dotsch V., Bumann D., RA Dikic I.; RT "Phosphorylation of the autophagy receptor optineurin restricts Salmonella RT growth."; RL Science 333:228-233(2011). RN [41] RP REVIEW ON FUNCTION, AND DOMAIN. RX PubMed=21042276; DOI=10.1038/onc.2010.493; RA Shen R.R., Hahn W.C.; RT "Emerging roles for the non-canonical IKKs in cancer."; RL Oncogene 30:631-641(2011). RN [42] RP FUNCTION, AND PHOSPHORYLATION BY IKBKB/IKKB. RX PubMed=21138416; DOI=10.1042/bj20101701; RA Clark K., Peggie M., Plater L., Sorcek R.J., Young E.R., Madwed J.B., RA Hough J., McIver E.G., Cohen P.; RT "Novel cross-talk within the IKK family controls innate immunity."; RL Biochem. J. 434:93-104(2011). RN [43] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=19010780; DOI=10.1074/jbc.m805905200; RA Verpooten D., Ma Y., Hou S., Yan Z., He B.; RT "Control of TANK-binding kinase 1-mediated signaling by the gamma(1)34.5 RT protein of herpes simplex virus 1."; RL J. Biol. Chem. 284:1097-1105(2009). RN [44] RP DEPHOSPHORYLATION AT SER-172. RX PubMed=22750291; DOI=10.1016/j.cellsig.2012.06.017; RA Zhao Y., Liang L., Fan Y., Sun S., An L., Shi Z., Cheng J., Jia W., Sun W., RA Mori-Akiyama Y., Zhang H., Fu S., Yang J.; RT "PPM1B negatively regulates antiviral response via dephosphorylating RT TBK1."; RL Cell. Signal. 24:2197-2204(2012). RN [45] RP INVOLVEMENT IN GLC1P. RX PubMed=22306015; DOI=10.1016/j.exer.2011.12.021; RA Kawase K., Allingham R.R., Meguro A., Mizuki N., Roos B., RA Solivan-Timpe F.M., Robin A.L., Ritch R., Fingert J.H.; RT "Confirmation of TBK1 duplication in normal tension glaucoma."; RL Exp. Eye Res. 96:178-180(2012). RN [46] RP INVOLVEMENT IN IIAE8, VARIANTS IIAE8 ALA-50 AND ALA-159, CHARACTERIZATION RP OF VARIANTS IIAE8 ALA-50 AND ALA-159, MUTAGENESIS OF LYS-38, RP PHOSPHORYLATION AT SER-172, AND FUNCTION. RX PubMed=22851595; DOI=10.1084/jem.20111316; RA Herman M., Ciancanelli M., Ou Y.H., Lorenzo L., Klaudel-Dreszler M., RA Pauwels E., Sancho-Shimizu V., Perez de Diego R., Abhyankar A., RA Israelsson E., Guo Y., Cardon A., Rozenberg F., Lebon P., Tardieu M., RA Heropolitanska-Pliszka E., Chaussabel D., White M.A., Abel L., Zhang S.Y., RA Casanova J.L.; RT "Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes RT simplex encephalitis of childhood."; RL J. Exp. Med. 209:1567-1582(2012). RN [47] RP UBIQUITINATION BY TRAIP. RX PubMed=22945920; DOI=10.1084/jem.20120024; RA Zhang M., Wang L., Zhao X., Zhao K., Meng H., Zhao W., Gao C.; RT "TRAF-interacting protein (TRIP) negatively regulates IFN-beta production RT and antiviral response by promoting proteasomal degradation of TANK-binding RT kinase 1."; RL J. Exp. Med. 209:1703-1711(2012). RN [48] RP UBIQUITINATION AT LYS-670 BY DTX4. RX PubMed=22388039; DOI=10.1038/ni.2239; RA Cui J., Li Y., Zhu L., Liu D., Songyang Z., Wang H.Y., Wang R.F.; RT "NLRP4 negatively regulates type I interferon signaling by targeting the RT kinase TBK1 for degradation via the ubiquitin ligase DTX4."; RL Nat. Immunol. 13:387-395(2012). RN [49] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-716, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [50] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24478431; DOI=10.1128/jvi.03021-13; RA Santiago F.W., Covaleda L.M., Sanchez-Aparicio M.T., Silvas J.A., RA Diaz-Vizarreta A.C., Patel J.R., Popov V., Yu X.J., Garcia-Sastre A., RA Aguilar P.V.; RT "Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic RT structures correlates with the inhibition of type I interferon responses."; RL J. Virol. 88:4572-4585(2014). RN [51] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=24706939; DOI=10.1093/jmcb/mju015; RA Ning Y.J., Wang M., Deng M., Shen S., Liu W., Cao W.C., Deng F., Wang Y.Y., RA Hu Z., Wang H.; RT "Viral suppression of innate immunity via spatial isolation of RT TBK1/IKKepsilon from mitochondrial antiviral platform."; RL J. Mol. Cell Biol. 6:324-337(2014). RN [52] RP INVOLVEMENT IN FTDALS4, AND VARIANTS FTDALS4 ILE-306; GLU-401 AND LYS-696. RX PubMed=25943890; DOI=10.1007/s00401-015-1436-x; RA Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M., RA Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., RA Nicholson A.M., DeTure M., Knopman D.S., Josephs K.A., Parisi J.E., RA Petersen R.C., Boylan K.B., Boeve B.F., Graff-Radford N.R., Veltman J.A., RA Gilissen C., Murray M.E., Dickson D.W., Rademakers R.; RT "Whole-genome sequencing reveals important role for TBK1 and OPTN mutations RT in frontotemporal lobar degeneration without motor neuron disease."; RL Acta Neuropathol. 130:77-92(2015). RN [53] RP INTERACTION WITH TICAM1. RX PubMed=25736436; DOI=10.15252/embr.201439637; RA Hu Y.H., Zhang Y., Jiang L.Q., Wang S., Lei C.Q., Sun M.S., Shu H.B., RA Liu Y.; RT "WDFY1 mediates TLR3/4 signaling by recruiting TRIF."; RL EMBO Rep. 16:447-455(2015). RN [54] RP INVOLVEMENT IN IIAE8, AND VARIANT IIAE8 VAL-207. RX PubMed=26513235; DOI=10.1038/gene.2015.46; RA Moerk N., Kofod-Olsen E., Soerensen K.B., Bach E., Oerntoft T.F., RA Oestergaard L., Paludan S.R., Christiansen M., Mogensen T.H.; RT "Mutations in the TLR3 signaling pathway and beyond in adult patients with RT herpes simplex encephalitis."; RL Genes Immun. 16:552-566(2015). RN [55] RP INVOLVEMENT IN FTDALS4, VARIANTS FTDALS4 HIS-47; CYS-105; THR-305; GLN-308; RP GLN-357; ARG-559; VAL-571; VAL-598; GLU-643 DEL AND LYS-696, AND RP CHARACTERIZATION OF VARIANTS FTDALS4 HIS-47; GLN-308; GLN-357; ARG-559 AND RP LYS-696. RX PubMed=25803835; DOI=10.1038/nn.4000; RA Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., Mueller K., RA Marroquin N., Nordin F., Huebers A., Weydt P., Pinto S., Press R., RA Millecamps S., Molko N., Bernard E., Desnuelle C., Soriani M.H., Dorst J., RA Graf E., Nordstroem U., Feiler M.S., Putz S., Boeckers T.M., Meyer T., RA Winkler A.S., Winkelman J., de Carvalho M., Thal D.R., Otto M., RA Braennstroem T., Volk A.E., Kursula P., Danzer K.M., Lichtner P., Dikic I., RA Meitinger T., Ludolph A.C., Strom T.M., Andersen P.M., Weishaupt J.H.; RT "Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal RT dementia."; RL Nat. Neurosci. 18:631-636(2015). RN [56] RP FUNCTION, AND CATALYTIC ACTIVITY. RX PubMed=25636800; DOI=10.1126/science.aaa2630; RA Liu S., Cai X., Wu J., Cong Q., Chen X., Li T., Du F., Ren J., Wu Y.T., RA Grishin N.V., Chen Z.J.; RT "Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF RT induces IRF3 activation."; RL Science 347:AAA2630-AAA2630(2015). RN [57] RP FUNCTION, AND INTERACTION WITH ICOS. RX PubMed=27135603; DOI=10.1038/ni.3463; RA Pedros C., Zhang Y., Hu J.K., Choi Y.S., Canonigo-Balancio A.J., RA Yates J.R. III, Altman A., Crotty S., Kong K.F.; RT "A TRAF-like motif of the inducible costimulator ICOS controls development RT of germinal center TFH cells via the kinase TBK1."; RL Nat. Immunol. 17:825-833(2016). RN [58] RP FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-670, AND MUTAGENESIS RP OF SER-172 AND LYS-670. RX PubMed=27692986; DOI=10.1016/j.molcel.2016.08.029; RA Lin M., Zhao Z., Yang Z., Meng Q., Tan P., Xie W., Qin Y., Wang R.F., RA Cui J.; RT "USP38 Inhibits Type I Interferon Signaling by Editing TBK1 Ubiquitination RT through NLRP4 Signalosome."; RL Mol. Cell 64:267-281(2016). RN [59] RP FUNCTION. RX PubMed=27103069; DOI=10.15252/embj.201593350; RA Sellier C., Campanari M.L., Julie Corbier C., Gaucherot A., RA Kolb-Cheynel I., Oulad-Abdelghani M., Ruffenach F., Page A., Ciura S., RA Kabashi E., Charlet-Berguerand N.; RT "Loss of C9ORF72 impairs autophagy and synergizes with polyQ Ataxin-2 to RT induce motor neuron dysfunction and cell death."; RL EMBO J. 35:1276-1297(2016). RN [60] RP INTERACTION WITH TRIM26, AND FUNCTION. RX PubMed=26611359; DOI=10.1093/jmcb/mjv068; RA Ran Y., Zhang J., Liu L.L., Pan Z.Y., Nie Y., Zhang H.Y., Wang Y.Y.; RT "Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate RT antiviral immune response."; RL J. Mol. Cell Biol. 8:31-43(2016). RN [61] RP UBIQUITINATION BY RNF128. RX PubMed=27776110; DOI=10.1038/ni.3588; RA Song G., Liu B., Li Z., Wu H., Wang P., Zhao K., Jiang G., Zhang L., RA Gao C.; RT "E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63- RT linked ubiquitination of TBK1."; RL Nat. Immunol. 17:1342-1351(2016). RN [62] RP INTERACTION WITH TTLL12 AND MAVS. RX PubMed=28011935; DOI=10.4049/jimmunol.1601194; RA Ju L.G., Zhu Y., Lei P.J., Yan D., Zhu K., Wang X., Li Q.L., Li X.J., RA Chen J.W., Li L.Y., Wu M.; RT "TTLL12 Inhibits the Activation of Cellular Antiviral Signaling through RT Interaction with VISA/MAVS."; RL J. Immunol. 198:1274-1284(2017). RN [63] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION). RX PubMed=28848048; DOI=10.1074/jbc.m117.805127; RA Ning Y.J., Feng K., Min Y.Q., Deng F., Hu Z., Wang H.; RT "Heartland virus NSs protein disrupts host defenses by blocking the TBK1 RT kinase-IRF3 transcription factor interaction and signaling required for RT interferon induction."; RL J. Biol. Chem. 292:16722-16733(2017). RN [64] RP INTERACTION WITH HEARTLAND VIRUS NSS (MICROBIAL INFECTION), INTERACTION RP WITH SFTSV NSS (MICROBIAL INFECTION), AND PHOSPHORYLATION AT SER-172. RX PubMed=28680969; DOI=10.1128/msphere.00234-17; RA Rezelj V.V., Li P., Chaudhary V., Elliott R.M., Jin D.Y., Brennan B.; RT "Differential Antagonism of Human Innate Immune Responses by Tick-Borne RT Phlebovirus Nonstructural Proteins."; RL MSphere 2:0-0(2017). RN [65] RP INTERACTION WITH TRIM23. RX PubMed=28871090; DOI=10.1038/s41564-017-0017-2; RA Sparrer K.M.J., Gableske S., Zurenski M.A., Parker Z.M., Full F., RA Baumgart G.J., Kato J., Pacheco-Rodriguez G., Liang C., Pornillos O., RA Moss J., Vaughan M., Gack M.U.; RT "TRIM23 mediates virus-induced autophagy via activation of TBK1."; RL Nat. Microbiol. 2:1543-1557(2017). RN [66] RP INTERACTION WITH HUMAN HERPESVIRUS 1 PROTEIN ICP34.5 (MICROBIAL INFECTION). RX PubMed=28904192; DOI=10.1128/jvi.01156-17; RA Manivanh R., Mehrbach J., Knipe D.M., Leib D.A.; RT "Role of Herpes Simplex Virus 1 gamma34.5 in the Regulation of IRF3 RT Signaling."; RL J. Virol. 91:0-0(2017). RN [67] RP INTERACTION WITH ZIKA VIRUS NON-STRUCTURAL PROTEIN 1 AND NON-STRUCTURAL RP PROTEIN 4B (MICROBIAL INFECTION). RX PubMed=28373913; DOI=10.1038/celldisc.2017.6; RA Wu Y., Liu Q., Zhou J., Xie W., Chen C., Wang Z., Yang H., Cui J.; RT "Zika virus evades interferon-mediated antiviral response through the co- RT operation of multiple nonstructural proteins in vitro."; RL Cell Discov. 3:17006-17006(2017). RN [68] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=29150432; DOI=10.15252/embj.201696164; RA Bodur C., Kazyken D., Huang K., Ekim Ustunel B., Siroky K.A., Tooley A.S., RA Gonzalez I.E., Foley D.H., Acosta-Jaquez H.A., Barnes T.M., Steinl G.K., RA Cho K.W., Lumeng C.N., Riddle S.M., Myers M.G. Jr., Fingar D.C.; RT "The IKK-related kinase TBK1 activates mTORC1 directly in response to RT growth factors and innate immune agonists."; RL EMBO J. 37:19-38(2018). RN [69] RP INTERACTION WITH CEP170. RX PubMed=30354798; DOI=10.1091/mbc.e18-02-0115; RA Baerenz F., Kschonsak Y.T., Meyer A., Jafarpour A., Lorenz H., Hoffmann I.; RT "Ccdc61 controls centrosomal localization of Cep170 and is required for RT spindle assembly and symmetry."; RL Mol. Biol. Cell 29:3105-3118(2018). RN [70] RP INTERACTION WITH TTC4; IKBKE; AZI2 AND TANK, AND SUBCELLULAR LOCATION. RX PubMed=29251827; DOI=10.1002/pmic.201700403; RA Shang J., Xia T., Han Q.Q., Zhao X., Hu M.M., Shu H.B., Guo L.; RT "Quantitative Proteomics Identified TTC4 as a TBK1 Interactor and a RT Positive Regulator of SeV-Induced Innate Immunity."; RL Proteomics 18:0-0(2018). RN [71] RP INTERACTION WITH SFTSV NSS (MICROBIAL INFECTION). RX PubMed=30021900; DOI=10.1128/jvi.00706-18; RA Moriyama M., Igarashi M., Koshiba T., Irie T., Takada A., Ichinohe T.; RT "Two Conserved Amino Acids within the NSs of Severe Fever with RT Thrombocytopenia Syndrome Phlebovirus Are Essential for Anti-interferon RT Activity."; RL J. Virol. 92:0-0(2018). RN [72] RP INTERACTION WITH HNRNPA2B1. RX PubMed=31320558; DOI=10.1126/science.aav0758; RA Wang L., Wen M., Cao X.; RT "Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to RT DNA viruses."; RL Science 0:0-0(2019). RN [73] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31530866; DOI=10.1038/s41598-019-49707-8; RA Antonia R.J., Castillo J., Herring L.E., Serafin D.S., Liu P., Graves L.M., RA Baldwin A.S., Hagan R.S.; RT "TBK1 limits mTORC1 by promoting phosphorylation of Raptor Ser877."; RL Sci. Rep. 9:13470-13470(2019). RN [74] RP INTERACTION WITH RNF144B. RX PubMed=31509299; DOI=10.1002/jlb.2a0819-055r; RA Zhang Z., Zhang L., Wang B., Zhu X., Zhao L., Chu C., Guo Q., Wei R., RA Yin X., Zhang Y., Li X.; RT "RNF144B inhibits LPS-induced inflammatory responses via binding TBK1."; RL J. Leukoc. Biol. 106:1303-1311(2019). RN [75] RP INTERACTION WITH CYLD. RX PubMed=32185393; DOI=10.1093/brain/awaa039; RA Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G., RA Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T., RA Thompson E.M., Blumbergs P., Short C.L., Field C.D., Panegyres P.K., RA Hecker J., Nicholson G., Shaw A.D., Fullerton J.M., Luty A.A., RA Schofield P.R., Brooks W.S., Rajan N., Bennett M.F., Bahlo M., RA Landers J.E., Piguet O., Hodges J.R., Halliday G.M., Topp S.D., Smith B.N., RA Shaw C.E., McCann E., Fifita J.A., Williams K.L., Atkin J.D., Blair I.P., RA Kwok J.B.; RT "CYLD is a causative gene for frontotemporal dementia - amyotrophic lateral RT sclerosis."; RL Brain 143:783-799(2020). RN [76] RP INTERACTION WITH SARS-COV-2 NON-STRUCTURAL PROTEIN 6 (MICROBIAL INFECTION), RP AND INTERACTION WITH SARS-COV-2 HELICASE (MICROBIAL INFECTION). RX PubMed=32979938; DOI=10.1016/j.celrep.2020.108234; RA Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D., RA Rajsbaum R., Shi P.Y.; RT "Evasion of Type I Interferon by SARS-CoV-2."; RL Cell Rep. 33:108234-108234(2020). RN [77] RP FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-38. RX PubMed=31709703; DOI=10.15252/embr.201948317; RA Herhaus L., Bhaskara R.M., Lystad A.H., Gestal-Mato U., RA Covarrubias-Pinto A., Bonn F., Simonsen A., Hummer G., Dikic I.; RT "TBK1-mediated phosphorylation of LC3C and GABARAP-L2 controls RT autophagosome shedding by ATG4 protease."; RL EMBO Rep. 21:e48317-e48317(2020). RN [78] RP INTERACTION WITH TRIM14, AND FUNCTION. RX PubMed=32404352; DOI=10.4049/jimmunol.1901511; RA Hoffpauir C.T., Bell S.L., West K.O., Jing T., Wagner A.R., Torres-Odio S., RA Cox J.S., West A.P., Li P., Patrick K.L., Watson R.O.; RT "TRIM14 Is a Key Regulator of the Type I IFN Response during Mycobacterium RT tuberculosis Infection."; RL J. Immunol. 205:153-167(2020). RN [79] RP INTERACTION WITH TAX1BP1. RX PubMed=33226137; DOI=10.15252/embj.2020104948; RA Ohnstad A.E., Delgado J.M., North B.J., Nasa I., Kettenbach A.N., RA Schultz S.W., Shoemaker C.J.; RT "Receptor-mediated clustering of FIP200 bypasses the role of LC3 lipidation RT in autophagy."; RL EMBO J. 39:e104948-e104948(2020). RN [80] RP INTERACTION WITH TRAF3IP3, AND UBIQUITINATION. RX PubMed=32366851; DOI=10.1038/s41467-020-16014-0; RA Deng M., Tam J.W., Wang L., Liang K., Li S., Zhang L., Guo H., Luo X., RA Zhang Y., Petrucelli A., Davis B.K., Conti B.J., June Brickey W., Ko C.C., RA Lei Y.L., Sun S., Ting J.P.; RT "TRAF3IP3 negatively regulates cytosolic RNA induced anti-viral signaling RT by promoting TBK1 K48 ubiquitination."; RL Nat. Commun. 11:2193-2193(2020). RN [81] RP INTERACTION WITH IKBKB. RX PubMed=32209697; DOI=10.1126/scisignal.aay0574; RA Metwally H., Tanaka T., Li S., Parajuli G., Kang S., Hanieh H., RA Hashimoto S., Chalise J.P., Gemechu Y., Standley D.M., Kishimoto T.; RT "Noncanonical STAT1 phosphorylation expands its transcriptional activity RT into promoting LPS-induced IL-6 and IL-12p40 production."; RL Sci. Signal. 13:0-0(2020). RN [82] RP INTERACTION WITH SARS-COV-2 M PROTEIN (MICROBIAL INFECTION), FUNCTION, AND RP UBIQUITINATION. RX PubMed=34084167; DOI=10.3389/fimmu.2021.662989; RA Sui L., Zhao Y., Wang W., Wu P., Wang Z., Yu Y., Hou Z., Tan G., Liu Q.; RT "SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through RT Ubiquitin-Mediated Degradation of TBK1."; RL Front. Immunol. 12:662989-662989(2021). RN [83] RP INTERACTION WITH HUMAN CYTOMEGALOVIRUS PROTEIN UL35 (MICROBIAL INFECTION). RX PubMed=32466380; DOI=10.3390/microorganisms8060790; RA Fabits M., Goncalves Magalhaes V., Chan B., Girault V., Elbasani E., RA Rossetti E., Saeland E., Messerle M., Pichlmair A., Lisnic V.J., RA Brinkmann M.M.; RT "The Cytomegalovirus Tegument Protein UL35 Antagonizes Pattern Recognition RT Receptor-Mediated Type I IFN Transcription."; RL Microorganisms 8:0-0(2020). RN [84] RP FUNCTION, INTERACTION WITH ASB8, AND SUBCELLULAR LOCATION. RX PubMed=32298923; DOI=10.1016/j.molimm.2020.03.011; RA Guo Y., Li R., Tan Z., Shi J., Fu Y., Song Y., Zhu M., Zhang L., Huang J.; RT "E3 ubiquitin ligase ASB8 negatively regulates interferon via regulating RT TBK1/IKKi homeostasis."; RL Mol. Immunol. 121:195-203(2020). RN [85] RP UBIQUITINATION BY TRAF7. RX PubMed=37086853; DOI=10.1016/j.virs.2023.04.005; RA Huang J.P., Yang Y.X., Chen T., Wang D.D., Li J., Xu L.G.; RT "TRAF7 negatively regulates the RLR signaling pathway by facilitating the RT K48-linked ubiquitination of TBK1."; RL Virol. Sin. 38:419-428(2023). RN [86] RP DEUBIQUITINATION BY EPSTEIN-BARR VIRUS PROTEIN BPLF1 (MICROBIAL INFECTION). RX PubMed=36802409; DOI=10.1371/journal.ppat.1011186; RA Lui W.Y., Bharti A., Wong N.M., Jangra S., Botelho M.G., Yuen K.S., RA Jin D.Y.; RT "Suppression of cGAS- and RIG-I-mediated innate immune signaling by RT Epstein-Barr virus deubiquitinase BPLF1."; RL PLoS Pathog. 19:e1011186-e1011186(2023). RN [87] RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, HOMODIMER, UBIQUITINATION AT LYS-30 AND LYS-401, AND RP MUTAGENESIS OF LYS-30; ASP-33; LYS-38; ASP-135; GLU-355; ARG-357; LYS-401; RP ARG-547; TYR-577; GLU-580; ILE-582 AND LYS-589. RX PubMed=23453971; DOI=10.1016/j.celrep.2013.01.034; RA Larabi A., Devos J.M., Ng S.L., Nanao M.H., Round A., Maniatis T., RA Panne D.; RT "Crystal structure and mechanism of activation of TANK-binding kinase 1."; RL Cell Rep. 3:734-746(2013). RN [88] RP X-RAY CRYSTALLOGRAPHY (2.61 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, ACTIVE SITE, AUTOPHOSPHORYLATION, HOMODIMER, INTERACTION WITH RP AZI2, AND MUTAGENESIS OF LYS-38; ASP-135; SER-172; LEU-316; TYR-325; RP GLU-355; GLU-448; HIS-459; ILE-466 AND PHE-470. RX PubMed=23453972; DOI=10.1016/j.celrep.2013.01.033; RA Tu D., Zhu Z., Zhou A.Y., Yun C.H., Lee K.E., Toms A.V., Li Y., Dunn G.P., RA Chan E., Thai T., Yang S., Ficarro S.B., Marto J.A., Jeon H., Hahn W.C., RA Barbie D.A., Eck M.J.; RT "Structure and ubiquitination-dependent activation of TANK-binding kinase RT 1."; RL Cell Rep. 3:747-758(2013). RN [89] RP X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-657 IN COMPLEX WITH INHIBITORS, RP FUNCTION, AND PHOSPHORYLATION AT SER-172. RX PubMed=23746807; DOI=10.1016/j.str.2013.04.025; RA Shu C., Sankaran B., Chaton C.T., Herr A.B., Mishra A., Peng J., Li P.; RT "Structural insights into the functions of TBK1 in innate antimicrobial RT immunity."; RL Structure 21:1137-1148(2013). RN [90] RP STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF 1-729 OF MUTANT ASN-135 RP IN COMPLEX WITH STING1, FUNCTION, INTERACTION WITH STING1, ACTIVE SITE, AND RP MUTAGENESIS OF TYR-577; ASN-578 AND GLN-581. RX PubMed=30842653; DOI=10.1038/s41586-019-1000-2; RA Zhang C., Shang G., Gui X., Zhang X., Bai X.C., Chen Z.J.; RT "Structural basis of STING binding with and phosphorylation by TBK1."; RL Nature 567:394-398(2019). RN [91] RP VARIANTS [LARGE SCALE ANALYSIS] GLN-271; GLU-291; HIS-296; ARG-410 AND RP ALA-464. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [92] RP VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; SER-388; RP THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, CHARACTERIZATION RP OF VARIANTS SER-24; LEU-152; ALA-159; 308-ARG--LEU-729 DEL; GLN-384; RP SER-388; THR-397; ILE-508; MET-522; THR-533; GLN-653 AND SER-659, AND RP FUNCTION. RX PubMed=32972995; DOI=10.1126/science.abd4570; RG COVID-STORM Clinicians; RG COVID Clinicians; RG Imagine COVID Group; RG French COVID Cohort Study Group; RG CoV-Contact Cohort; RG Amsterdam UMC Covid-19 Biobank; RG COVID Human Genetic Effort; RG NIAID-USUHS/TAGC COVID Immunity Group; RA Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., RA Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K., RA Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y., RA Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L., RA Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.H., RA Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P., RA Neehus A.L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F., RA Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlueter A., Le Voyer T., RA Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F., RA Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z., RA Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A., RA Bettini L.R., D'Angio' M., Bonfanti P., Imberti L., Sottini A., Paghera S., RA Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C., RA Vandernoot I., Goffard J.C., Smits G., Migeotte I., Haerynck F., RA Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.E., Keles S., RA Coelkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela S.N., RA Rodriguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y., RA Duval X., Laouenan C., Snow A.L., Dalgard C.L., Milner J.D., Vinh D.C., RA Mogensen T.H., Marr N., Spaan A.N., Boisson B., Boisson-Dupuis S., RA Bustamante J., Puel A., Ciancanelli M.J., Meyts I., Maniatis T., RA Soumelis V., Amara A., Nussenzweig M., Garcia-Sastre A., Krammer F., RA Pujol A., Duffy D., Lifton R.P., Zhang S.Y., Gorochov G., Beziat V., RA Jouanguy E., Sancho-Shimizu V., Rice C.M., Abel L., Notarangelo L.D., RA Cobat A., Su H.C., Casanova J.L.; RT "Inborn errors of type I IFN immunity in patients with life-threatening RT COVID-19."; RL Science 370:0-0(2020). RN [93] RP VARIANTS AIARV ASP-212; 440-ARG--LEU-729 DEL AND 619-TRP--LEU-729 DEL, RP CHARACTERIZATION OF VARIANTS AIARV ASP-212 AND 619-TRP--LEU-729 DEL, RP INVOLVEMENT IN AIARV, AND FUNCTION. RX PubMed=34363755; DOI=10.1016/j.cell.2021.07.026; RA Taft J., Markson M., Legarda D., Patel R., Chan M., Malle L., RA Richardson A., Gruber C., Martin-Fernandez M., Mancini G.M.S., RA van Laar J.A.M., van Pelt P., Buta S., Wokke B.H.A., Sabli I.K.D., RA Sancho-Shimizu V., Chavan P.P., Schnappauf O., Khubchandani R., RA Cueceoglu M.K., Oezen S., Kastner D.L., Ting A.T., Aksentijevich I., RA Hollink I.H.I.M., Bogunovic D.; RT "Human TBK1 deficiency leads to autoinflammation driven by TNF-induced cell RT death."; RL Cell 184:4447-4463.e20(2021). RN [94] RP VARIANT AIARV 440-ARG--LEU-729 DEL. RX PubMed=32447396; DOI=10.1093/rheumatology/keaa165; RA Kosukcu C., Taskiran E.Z., Batu E.D., Sag E., Bilginer Y., Alikasifoglu M., RA Ozen S.; RT "Whole exome sequencing in unclassified autoinflammatory diseases: more RT monogenic diseases in the pipeline?"; RL Rheumatology 60:607-616(2021). RN [95] RP FUNCTION, HOMODIMERIZATION, INTERACTION WITH IRF3; MAVS AND ZNF268, RP METHYLATION AT LYS-607, AND MUTAGENESIS OF LYS-584 AND LYS-607. RX PubMed=37926288; DOI=10.1016/j.jbc.2023.105428; RA Liu Y., Yin W., Zeng X., Fan J., Liu C., Gao M., Huang Z., Sun G., Guo M.; RT "TBK1-stabilized ZNF268a recruits SETD4 to methylate TBK1 for efficient RT interferon signaling."; RL J. Biol. Chem. 299:105428-105428(2023). CC -!- FUNCTION: Serine/threonine kinase that plays an essential role in CC regulating inflammatory responses to foreign agents (PubMed:10581243, CC PubMed:11839743, PubMed:12692549, PubMed:12702806, PubMed:14703513, CC PubMed:15367631, PubMed:15485837, PubMed:18583960, PubMed:21138416, CC PubMed:23453971, PubMed:23453972, PubMed:23746807, PubMed:25636800, CC PubMed:26611359, PubMed:32404352, PubMed:34363755, PubMed:32298923). CC Following activation of toll-like receptors by viral or bacterial CC components, associates with TRAF3 and TANK and phosphorylates CC interferon regulatory factors (IRFs) IRF3 and IRF7 as well as DDX3X CC (PubMed:12692549, PubMed:12702806, PubMed:14703513, PubMed:15367631, CC PubMed:18583960, PubMed:25636800). This activity allows subsequent CC homodimerization and nuclear translocation of the IRFs leading to CC transcriptional activation of pro-inflammatory and antiviral genes CC including IFNA and IFNB (PubMed:12702806, PubMed:15367631, CC PubMed:25636800, PubMed:32972995). In order to establish such an CC antiviral state, TBK1 form several different complexes whose CC composition depends on the type of cell and cellular stimuli CC (PubMed:23453971, PubMed:23453972, PubMed:23746807). Plays a key role CC in IRF3 activation: acts by first phosphorylating innate adapter CC proteins MAVS, STING1 and TICAM1 on their pLxIS motif, leading to CC recruitment of IRF3, thereby licensing IRF3 for phosphorylation by TBK1 CC (PubMed:25636800, PubMed:30842653, PubMed:37926288). Phosphorylated CC IRF3 dissociates from the adapter proteins, dimerizes, and then enters CC the nucleus to induce expression of interferons (PubMed:25636800). CC Thus, several scaffolding molecules including FADD, TRADD, MAVS, AZI2, CC TANK or TBKBP1/SINTBAD can be recruited to the TBK1-containing- CC complexes (PubMed:21931631). Under particular conditions, functions as CC a NF-kappa-B effector by phosphorylating NF-kappa-B inhibitor CC alpha/NFKBIA, IKBKB or RELA to translocate NF-Kappa-B to the nucleus CC (PubMed:10783893, PubMed:15489227). Restricts bacterial proliferation CC by phosphorylating the autophagy receptor OPTN/Optineurin on 'Ser-177', CC thus enhancing LC3 binding affinity and antibacterial autophagy CC (PubMed:21617041). Phosphorylates SMCR8 component of the C9orf72-SMCR8 CC complex, promoting autophagosome maturation (PubMed:27103069). CC Phosphorylates ATG8 proteins MAP1LC3C and GABARAPL2, thereby preventing CC their delipidation and premature removal from nascent autophagosomes CC (PubMed:31709703). Seems to play a role in energy balance regulation by CC sustaining a state of chronic, low-grade inflammation in obesity, which CC leads to a negative impact on insulin sensitivity (By similarity). CC Attenuates retroviral budding by phosphorylating the endosomal sorting CC complex required for transport-I (ESCRT-I) subunit VPS37C CC (PubMed:21270402). Phosphorylates Borna disease virus (BDV) P protein CC (PubMed:16155125). Plays an essential role in the TLR3- and IFN- CC dependent control of herpes virus HSV-1 and HSV-2 infections in the CC central nervous system (PubMed:22851595). Acts both as a positive and CC negative regulator of the mTORC1 complex, depending on the context: CC activates mTORC1 in response to growth factors by catalyzing CC phosphorylation of MTOR, while it limits the mTORC1 complex by CC promoting phosphorylation of RPTOR (PubMed:29150432, PubMed:31530866). CC Acts as a positive regulator of the mTORC2 complex by mediating CC phosphorylation of MTOR, leading to increased phosphorylation and CC activation of AKT1 (By similarity). Phosphorylates and activates AKT1 CC (PubMed:21464307). Involved in the regulation of TNF-induced RIPK1- CC mediated cell death, probably acting via CYLD phosphorylation that in CC turn controls RIPK1 ubiquitination status (PubMed:34363755). Also CC participates in the differentiation of T follicular regulatory cells CC together with the receptor ICOS (PubMed:27135603). CC {ECO:0000250|UniProtKB:Q9WUN2, ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:11839743, CC ECO:0000269|PubMed:12692549, ECO:0000269|PubMed:12702806, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:15367631, CC ECO:0000269|PubMed:15485837, ECO:0000269|PubMed:15489227, CC ECO:0000269|PubMed:16155125, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:23746807, ECO:0000269|PubMed:25636800, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27103069, CC ECO:0000269|PubMed:27135603, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31530866, CC ECO:0000269|PubMed:31709703, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32972995, ECO:0000269|PubMed:34363755, CC ECO:0000269|PubMed:37926288}. CC -!- CATALYTIC ACTIVITY: CC Reaction=L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + CC H(+); Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA- CC COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:29150432, CC ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703}; CC -!- CATALYTIC ACTIVITY: CC Reaction=L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + CC ADP + H(+); Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA- CC COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, CC ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.1; CC Evidence={ECO:0000269|PubMed:10783893, ECO:0000269|PubMed:14703513, CC ECO:0000269|PubMed:15367631, ECO:0000269|PubMed:18583960, CC ECO:0000269|PubMed:21138416, ECO:0000269|PubMed:21270402, CC ECO:0000269|PubMed:21464307, ECO:0000269|PubMed:21617041, CC ECO:0000269|PubMed:25636800}; CC -!- SUBUNIT: Homodimer (PubMed:21145761, PubMed:37926288). Interacts with CC DDX3X, TIRAP and TRAF2 (PubMed:10581243, PubMed:14530355). Part of a CC ternary complex consisting of TANK, TRAF2 and TBK1 (PubMed:10581243). CC Interacts with AZI2, TANK and TBKBP1; these interactions are mutually CC exclusive and mediate TBK1 activation (PubMed:10581243, CC PubMed:14560022, PubMed:21931631, PubMed:23453972, PubMed:29251827). CC Interacts with GSK3B; this interaction promotes TBK1 self-association CC and autophosphorylation (PubMed:21145761). Interacts with SIKE1; SIKE1 CC is associated with TBK1 under physiological condition and dissociated CC from TBK1 upon viral infection or TLR3 stimulation (PubMed:16281057). CC Interacts with IRF3, leading to IRF3 phosphorylation (PubMed:14703513, CC PubMed:25636800, PubMed:37926288). Interacts with RIGI CC (PubMed:16281057). Interacts with CYLD (PubMed:18636086, CC PubMed:32185393). Interacts with OPTN and TRAF3 (PubMed:20174559). CC Interacts with SRC (PubMed:19419966). Interacts with the exocyst CC complex subunit SEC5/EXOC2; this interaction is sufficient to trigger CC TBK1 activity (PubMed:17018283). Interacts with STING1, leading to CC STING1 phosphorylation (PubMed:19416887, PubMed:25636800, CC PubMed:30842653). Interacts with IFIT3 (via N-terminus) CC (PubMed:21813773). Interacts with MAVS; interaction only takes place in CC the presence of IFIT3 and leads to MAVS phosphorylation CC (PubMed:21813773, PubMed:25636800, PubMed:28011935, PubMed:37926288). CC Interacts (via protein kinase domain) with TTLL12 (via TTL domain); the CC interaction prevents MAVS binding to TBK1 (PubMed:28011935). Interacts CC with TICAM1; this interaction is enhanced in the presence of WDFY1 and CC leads to TICAM1 phosphorylation (PubMed:14530355, PubMed:14739303, CC PubMed:25636800, PubMed:25736436). Interacts with TRIM26 CC (PubMed:26611359). Interacts with TRIM23 (PubMed:28871090). Interacts CC with TTC4 and IKBKE (PubMed:29251827). Interacts with HNRNPA2B1 CC (PubMed:31320558). Interacts with DDX3X (PubMed:20375222). Interacts CC with TRIM14 (PubMed:32404352). Interacts with CEP170; efficient complex CC formation may be dependent on the presence of CCDC61 (PubMed:30354798). CC Interacts with TRAF3IP3 (PubMed:32366851). Interacts with HSP90AA1; the CC interaction mediates TBK1 association with TOMM70 (PubMed:20628368). CC Interacts with TAX1BP1 (PubMed:33226137). Interacts with kinase IKBKB; CC the complex interacts with STAT1, leading to phosphorylation of STAT1 CC on 'Thr-749' by IKBKB (PubMed:32209697). Interacts with ICOS; this CC interaction is critical for the maturation of T follicular regulatory CC cells (PubMed:27135603). Interacts with RNF144B; this interaction CC prevents TBK1 phosphorylation and subsequent activation CC (PubMed:31509299). Interacts with ASB8; this interaction promotes TBK1 CC proteasomal degradation (PubMed:32298923). Forms a ternary complex with CC ZNF268 and SETD4; the interaction with SETD4 is ZNF268-dependent and CC leads to TBK1 monomethylation, which enhances its interaction with IRF3 CC and MAVS (PubMed:37926288). {ECO:0000269|PubMed:10581243, CC ECO:0000269|PubMed:14530355, ECO:0000269|PubMed:14560022, CC ECO:0000269|PubMed:14703513, ECO:0000269|PubMed:14739303, CC ECO:0000269|PubMed:16281057, ECO:0000269|PubMed:17018283, CC ECO:0000269|PubMed:18636086, ECO:0000269|PubMed:19416887, CC ECO:0000269|PubMed:19419966, ECO:0000269|PubMed:20174559, CC ECO:0000269|PubMed:20375222, ECO:0000269|PubMed:20628368, CC ECO:0000269|PubMed:21145761, ECO:0000269|PubMed:21813773, CC ECO:0000269|PubMed:21931631, ECO:0000269|PubMed:23453972, CC ECO:0000269|PubMed:25636800, ECO:0000269|PubMed:25736436, CC ECO:0000269|PubMed:26611359, ECO:0000269|PubMed:27135603, CC ECO:0000269|PubMed:28011935, ECO:0000269|PubMed:28871090, CC ECO:0000269|PubMed:29251827, ECO:0000269|PubMed:30354798, CC ECO:0000269|PubMed:30842653, ECO:0000269|PubMed:31320558, CC ECO:0000269|PubMed:31509299, ECO:0000269|PubMed:32185393, CC ECO:0000269|PubMed:32209697, ECO:0000269|PubMed:32298923, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:32404352, CC ECO:0000269|PubMed:33226137, ECO:0000269|PubMed:37926288}. CC -!- SUBUNIT: (Microbial infection) Interacts with Borna disease virus (BDV) CC P protein leading to its phosphorylation. CC {ECO:0000269|PubMed:16155125}. CC -!- SUBUNIT: (Microbial infection) Interacts with Ebola virus protein VP35. CC {ECO:0000269|PubMed:19153231}. CC -!- SUBUNIT: (Microbial infection) Interacts with HCV NS3; this interaction CC leads to inhibition of cellular antiviral response by blocking CC necessary interactions between the TBK1 and its substrates IRF3 and CC IRF7. {ECO:0000269|PubMed:15841462}. CC -!- SUBUNIT: (Microbial infection) Interacts with human herpesvirus 1 CC protein ICP34.5. {ECO:0000269|PubMed:19010780, CC ECO:0000269|PubMed:28904192}. CC -!- SUBUNIT: (Microbial infection) Interacts with Zika virus non-structural CC protein 1/NS1 and non-structural protein 4B/NS4B. CC {ECO:0000269|PubMed:28373913}. CC -!- SUBUNIT: (Microbial infection) Interacts with SARS-CoV-2 non-structural CC protein 6; this interaction decreases IRF3 phosphorylation by 57%, CC which leads to reduced IFN-beta (IFNB) production (PubMed:32979938). CC Interacts with SARS-CoV-2 helicase; this interaction inhibits TBK1 CC phosphorylation and decreases IRF3 phosphorylation by 75%, which leads CC to reduced IFN-beta production (PubMed:32979938). Interacts with SARS- CC CoV-2 M protein; the interaction promotes TBK1 degradation via 'Lys- CC 48'-linked ubiquitination (PubMed:34084167). CC {ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:34084167}. CC -!- SUBUNIT: (Microbial infection) Interacts with human cytomegalovirus CC protein UL35; this interaction inhibits type I interferon production. CC {ECO:0000269|PubMed:32466380}. CC -!- SUBUNIT: (Microbial infection) Interacts with heartland virus NSs; this CC interaction antagonizes TBK1 phosphorylation and inhibits TBK1-IRF3 CC interaction and thus the establishment of an antiviral state. CC {ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:28848048}. CC -!- SUBUNIT: (Microbial infection) Interacts (via N-terminus) with Severe CC fever with thrombocytopenia virus (SFTSV) NSs; this interaction CC antagonizes TBK1 phosphorylation and sequesters TBK1 in NSs-induced CC cytoplasmic inclusion bodies thereby inhibiting the IFN responses. CC {ECO:0000269|PubMed:24478431, ECO:0000269|PubMed:24706939, CC ECO:0000269|PubMed:28680969, ECO:0000269|PubMed:30021900}. CC -!- INTERACTION: CC Q9UHD2; Q9UKV8: AGO2; NbExp=2; IntAct=EBI-356402, EBI-528269; CC Q9UHD2; Q7Z3C6: ATG9A; NbExp=2; IntAct=EBI-356402, EBI-727146; CC Q9UHD2; Q9H6S1: AZI2; NbExp=7; IntAct=EBI-356402, EBI-359973; CC Q9UHD2; Q13137: CALCOCO2; NbExp=10; IntAct=EBI-356402, EBI-739580; CC Q9UHD2; Q6DT37: CDC42BPG; NbExp=3; IntAct=EBI-356402, EBI-689124; CC Q9UHD2; P08238: HSP90AB1; NbExp=3; IntAct=EBI-356402, EBI-352572; CC Q9UHD2; Q9Y6W8: ICOS; NbExp=5; IntAct=EBI-356402, EBI-3922712; CC Q9UHD2; Q14164: IKBKE; NbExp=5; IntAct=EBI-356402, EBI-307369; CC Q9UHD2; Q9Y6K9: IKBKG; NbExp=6; IntAct=EBI-356402, EBI-81279; CC Q9UHD2; Q14653: IRF3; NbExp=10; IntAct=EBI-356402, EBI-2650369; CC Q9UHD2; Q92985: IRF7; NbExp=2; IntAct=EBI-356402, EBI-968267; CC Q9UHD2; Q9H492: MAP1LC3A; NbExp=2; IntAct=EBI-356402, EBI-720768; CC Q9UHD2; Q9GZQ8: MAP1LC3B; NbExp=2; IntAct=EBI-356402, EBI-373144; CC Q9UHD2; Q7Z434: MAVS; NbExp=6; IntAct=EBI-356402, EBI-995373; CC Q9UHD2; Q86YT6: MIB1; NbExp=2; IntAct=EBI-356402, EBI-2129148; CC Q9UHD2; Q96AX9: MIB2; NbExp=2; IntAct=EBI-356402, EBI-2130249; CC Q9UHD2; Q9NVV4: MTPAP; NbExp=2; IntAct=EBI-356402, EBI-2556166; CC Q9UHD2; Q96CV9: OPTN; NbExp=17; IntAct=EBI-356402, EBI-748974; CC Q9UHD2; O14730: RIOK3; NbExp=3; IntAct=EBI-356402, EBI-1047061; CC Q9UHD2; P42226: STAT6; NbExp=7; IntAct=EBI-356402, EBI-1186478; CC Q9UHD2; Q86WV6: STING1; NbExp=9; IntAct=EBI-356402, EBI-2800345; CC Q9UHD2; O75558: STX11; NbExp=5; IntAct=EBI-356402, EBI-714135; CC Q9UHD2; Q92844: TANK; NbExp=15; IntAct=EBI-356402, EBI-356349; CC Q9UHD2; Q9UHD2: TBK1; NbExp=2; IntAct=EBI-356402, EBI-356402; CC Q9UHD2; A7MCY6: TBKBP1; NbExp=9; IntAct=EBI-356402, EBI-359969; CC Q9UHD2; Q8IUC6: TICAM1; NbExp=3; IntAct=EBI-356402, EBI-525995; CC Q9UHD2; Q12933: TRAF2; NbExp=9; IntAct=EBI-356402, EBI-355744; CC Q9UHD2; Q13114: TRAF3; NbExp=4; IntAct=EBI-356402, EBI-357631; CC Q9UHD2; O95801: TTC4; NbExp=5; IntAct=EBI-356402, EBI-1050890; CC Q9UHD2; P40222: TXLNA; NbExp=8; IntAct=EBI-356402, EBI-359793; CC Q9UHD2; Q62167: Ddx3x; Xeno; NbExp=8; IntAct=EBI-356402, EBI-773173; CC Q9UHD2; O41932: GAMMAHV.ORF11; Xeno; NbExp=4; IntAct=EBI-356402, EBI-9544132; CC Q9UHD2; P0DTC5: M; Xeno; NbExp=10; IntAct=EBI-356402, EBI-25475853; CC Q9UHD2; P59596: M; Xeno; NbExp=5; IntAct=EBI-356402, EBI-25487824; CC Q9UHD2; W5VXH5: NSs; Xeno; NbExp=3; IntAct=EBI-356402, EBI-9543922; CC Q9UHD2; PRO_0000449630 [P0DTD1]: rep; Xeno; NbExp=6; IntAct=EBI-356402, EBI-25475888; CC Q9UHD2; Q60803: Traf3; Xeno; NbExp=2; IntAct=EBI-356402, EBI-520135; CC Q9UHD2; Q8BHN1: Txlng; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6116854; CC Q9UHD2; Q05127: VP35; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6148294; CC Q9UHD2; I6W9F2; Xeno; NbExp=6; IntAct=EBI-356402, EBI-9518472; CC Q9UHD2; K7Y1A2; Xeno; NbExp=2; IntAct=EBI-356402, EBI-8788634; CC Q9UHD2; PRO_0000037572 [P27958]; Xeno; NbExp=2; IntAct=EBI-356402, EBI-6919131; CC Q9UHD2; PRO_0000037573 [P27958]; Xeno; NbExp=4; IntAct=EBI-356402, EBI-3649474; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15485837, CC ECO:0000269|PubMed:21813773, ECO:0000269|PubMed:29251827, CC ECO:0000269|PubMed:32298923}. Note=Upon mitogen stimulation or CC triggering of the immune system, TBK1 is recruited to the exocyst by CC EXOC2. {ECO:0000269|PubMed:17018283}. CC -!- TISSUE SPECIFICITY: Ubiquitous with higher expression in testis. CC Expressed in the ganglion cells, nerve fiber layer and microvasculature CC of the retina. {ECO:0000269|PubMed:10783893, CC ECO:0000269|PubMed:21447600}. CC -!- DOMAIN: Comprises A N-terminal kinase domain, a ubiquitin-like domain CC and a C-terminal coiled-coil region mediating homodimerization. CC {ECO:0000269|PubMed:17599067, ECO:0000269|PubMed:21042276}. CC -!- PTM: Autophosphorylation at Ser-172 activates the kinase, and is an CC essential step for virus-triggered signaling. Phosphorylated by CC IKBKB/IKKB at Ser-172. Phosphorylation requires homodimerization and CC ubiquitination at Lys-30 and Lys-401. Dephosphorylated at Ser-172 by CC PPM1B and this negatively regulates its role in mediating antiviral CC response. {ECO:0000269|PubMed:11839743, ECO:0000269|PubMed:21138416, CC ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23746807}. CC -!- PTM: 'Lys-63'-linked polyubiquitination by MIB1 after RNA virus CC infection, or by NRDP1 after LPS stimulation at Lys-30 and Lys-401, CC participates in kinase activation. 'Lys-48'-linked polyubiquitination CC at Lys-670 by DTX4 leads to proteasomal degradation. 'Lys-48'-linked CC polyubiquitination by TRAIP also leads to proteasomal degradation. CC 'Lys-48'-linked polyubiquitination by TRAF7; leading to proteasomal CC degradation (PubMed:37086853). 'Lys-63'-linked polyubiquitination by CC RNF128 at Lys-30 and Lys-401 leads to the activation of antiviral CC responses. 'Lys-48'-linked polyubiquitination after 'lys-33'-linked CC deubiquitination by USP38 promotes TBK1 degradation (PubMed:27692986). CC {ECO:0000269|PubMed:22388039, ECO:0000269|PubMed:23453971, CC ECO:0000269|PubMed:27692986, ECO:0000269|PubMed:27776110, CC ECO:0000269|PubMed:32366851, ECO:0000269|PubMed:37086853}. CC -!- PTM: (Microbial infection) Interaction with SARS-CoV-2 M protein CC induces 'Lys-48'-linked ubiquitination which leads to proteasomal CC degradation. {ECO:0000269|PubMed:34084167}. CC -!- PTM: (Microbial infection) Deubiquitinated by Epstein-Barr virus BPLF1 CC on both 'Lys-48' and 'Lys-63'-linked ubiquitin chains; leading to CC inhibition of type I interfewron production. CC {ECO:0000269|PubMed:36802409}. CC -!- PTM: Monomethylation at Lys-607 by SETD4 maximizes TBK1 activation and CC promotes efficient interferon signaling. {ECO:0000269|PubMed:37926288}. CC -!- DISEASE: Glaucoma 1, open angle, P (GLC1P) [MIM:177700]: A form of CC primary open angle glaucoma (POAG). POAG is characterized by a specific CC pattern of optic nerve and visual field defects. The angle of the CC anterior chamber of the eye is open, and usually the intraocular CC pressure is increased. However, glaucoma can occur at any intraocular CC pressure. The disease is generally asymptomatic until the late stages, CC by which time significant and irreversible optic nerve damage has CC already taken place. GLC1P is characterized by early onset, thin CC central corneas and low intraocular pressure. CC {ECO:0000269|PubMed:21447600, ECO:0000269|PubMed:22306015}. Note=The CC disease may be caused by variants affecting the gene represented in CC this entry. A copy number variation on chromosome 12q14 consisting of a CC 300 kb duplication that includes TBK1, XPOT, RASSF3 and GNS has been CC found in individuals affected by glaucoma. TBK1 is the most likely CC candidate for the disorder (PubMed:21447600). CC {ECO:0000269|PubMed:21447600}. CC -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 CC (FTDALS4) [MIM:616439]: A neurodegenerative disorder characterized by CC frontotemporal dementia and/or amyotrophic lateral sclerosis in CC affected individuals. There is high intrafamilial variation. CC Frontotemporal dementia is characterized by frontal and temporal lobe CC atrophy associated with neuronal loss, gliosis, and dementia. Patients CC exhibit progressive changes in social, behavioral, and/or language CC function. Amyotrophic lateral sclerosis is characterized by the death CC of motor neurons in the brain, brainstem, and spinal cord, resulting in CC fatal paralysis. {ECO:0000269|PubMed:25803835, CC ECO:0000269|PubMed:25943890}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- DISEASE: Encephalopathy, acute, infection-induced, 8, herpes-specific CC (IIAE8) [MIM:617900]: A rare, often fatal complication of herpes CC simplex infection, caused by virus spreading in the central nervous CC system. Disease manifestations include low-grade fever, severe CC headache, nausea, vomiting, and lethargy. Neurological features include CC confusion, acute memory disturbances, disorientation, behavioral CC changes, hemiparesis and seizures. {ECO:0000269|PubMed:22851595, CC ECO:0000269|PubMed:26513235}. Note=Disease susceptibility is associated CC with variants affecting the gene represented in this entry. CC -!- DISEASE: Autoinflammation with arthritis and vasculitis (AIARV) CC [MIM:620880]: An autosomal recessive disorder characterized by onset of CC chronic and systemic autoinflammation in infancy or early childhood. CC Affected individuals have recurrent fever, erythematous skin rashes, CC vasculitis, oral aphthous lesions, and polyarthritis. Additional CC variable features are poor overall growth, microcytic anemia, mild CC intellectual disability, and seizures. {ECO:0000269|PubMed:32447396, CC ECO:0000269|PubMed:34363755}. Note=The disease is caused by variants CC affecting the gene represented in this entry. CC -!- MISCELLANEOUS: In cancer cells, pathological TBK1 activation promotes CC oncogenic transformation by suppressing programmed cell death. CC Mechanistically, the RALB-SEC5/EXOC2-TBK1 signaling cascade seems to CC participate in both innate immune signaling and cell transformation. CC Additionally, TBK1 supports oncogenesis by directly phosphorylating and CC activating AKT1 at the exocyst (PubMed:21042276). CC {ECO:0000305|PubMed:21042276}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein CC kinase family. I-kappa-B kinase subfamily. {ECO:0000255|PROSITE- CC ProRule:PRU00159}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA92129.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF191838; AAF05989.1; -; mRNA. DR EMBL; AF174536; AAF69106.1; -; mRNA. DR EMBL; AK002192; BAA92129.1; ALT_INIT; mRNA. DR EMBL; AK291039; BAF83728.1; -; mRNA. DR EMBL; CH471054; EAW97133.1; -; Genomic_DNA. DR EMBL; BC034950; AAH34950.1; -; mRNA. DR CCDS; CCDS8968.1; -. DR RefSeq; NP_037386.1; NM_013254.4. DR RefSeq; XP_005268866.1; XM_005268809.2. DR RefSeq; XP_005268867.1; XM_005268810.2. DR RefSeq; XP_054227832.1; XM_054371857.1. DR RefSeq; XP_054227833.1; XM_054371858.1. DR PDB; 4EFO; X-ray; 1.77 A; A/B=302-383. DR PDB; 4EUT; X-ray; 2.60 A; A/B=2-385. DR PDB; 4EUU; X-ray; 1.80 A; A/B=2-308. DR PDB; 4IM0; X-ray; 2.40 A; A=1-657. DR PDB; 4IM2; X-ray; 2.50 A; A=1-657. DR PDB; 4IM3; X-ray; 3.34 A; A=1-657. DR PDB; 4IW0; X-ray; 4.00 A; A=2-657. DR PDB; 4IWO; X-ray; 2.61 A; A=2-657. DR PDB; 4IWP; X-ray; 3.06 A; A=2-657. DR PDB; 4IWQ; X-ray; 3.00 A; A=2-657. DR PDB; 5EOA; X-ray; 2.50 A; C/D=677-729. DR PDB; 5EOF; X-ray; 2.05 A; C/D=677-729. DR PDB; 5EP6; X-ray; 1.45 A; B/D=677-729. DR PDB; 5W5V; X-ray; 3.65 A; A=1-657. DR PDB; 6BNY; X-ray; 3.34 A; A=1-657. DR PDB; 6BOD; X-ray; 3.20 A; A=1-657. DR PDB; 6BOE; X-ray; 3.60 A; A=1-657. DR PDB; 6CQ0; X-ray; 3.19 A; A=1-657. DR PDB; 6CQ4; X-ray; 3.20 A; A=1-657. DR PDB; 6CQ5; X-ray; 3.35 A; A=1-657. DR PDB; 6NT9; EM; 3.30 A; A/B=1-729. DR PDB; 6O8B; X-ray; 3.40 A; A/B=2-657. DR PDB; 6RSR; X-ray; 3.15 A; A=2-657. DR PDB; 6RST; X-ray; 3.29 A; A=2-657. DR PDB; 6RSU; X-ray; 2.75 A; A=2-657. DR PDBsum; 4EFO; -. DR PDBsum; 4EUT; -. DR PDBsum; 4EUU; -. DR PDBsum; 4IM0; -. DR PDBsum; 4IM2; -. DR PDBsum; 4IM3; -. DR PDBsum; 4IW0; -. DR PDBsum; 4IWO; -. DR PDBsum; 4IWP; -. DR PDBsum; 4IWQ; -. DR PDBsum; 5EOA; -. DR PDBsum; 5EOF; -. DR PDBsum; 5EP6; -. DR PDBsum; 5W5V; -. DR PDBsum; 6BNY; -. DR PDBsum; 6BOD; -. DR PDBsum; 6BOE; -. DR PDBsum; 6CQ0; -. DR PDBsum; 6CQ4; -. DR PDBsum; 6CQ5; -. DR PDBsum; 6NT9; -. DR PDBsum; 6O8B; -. DR PDBsum; 6RSR; -. DR PDBsum; 6RST; -. DR PDBsum; 6RSU; -. DR AlphaFoldDB; Q9UHD2; -. DR EMDB; EMD-0506; -. DR SMR; Q9UHD2; -. DR BioGRID; 118878; 435. DR ComplexPortal; CPX-6018; STING-TRAF3-TBK1 complex. DR ComplexPortal; CPX-6038; TBK1-IKKepsilon-NAP1 complex. DR ComplexPortal; CPX-6089; TBK1-IKKepsilon-TANK complex. DR ComplexPortal; CPX-6090; TBK1-IKKepsilon-SINTBAD complex. DR CORUM; Q9UHD2; -. DR DIP; DIP-27529N; -. DR FunCoup; Q9UHD2; 4748. DR IntAct; Q9UHD2; 197. DR MINT; Q9UHD2; -. DR STRING; 9606.ENSP00000329967; -. DR BindingDB; Q9UHD2; -. DR ChEMBL; CHEMBL5408; -. DR DrugBank; DB12010; Fostamatinib. DR DrugCentral; Q9UHD2; -. DR GuidetoPHARMACOLOGY; 2237; -. DR GlyGen; Q9UHD2; 1 site, 1 N-linked glycan (1 site). DR iPTMnet; Q9UHD2; -. DR MetOSite; Q9UHD2; -. DR PhosphoSitePlus; Q9UHD2; -. DR BioMuta; TBK1; -. DR DMDM; 74761953; -. DR CPTAC; CPTAC-2972; -. DR CPTAC; CPTAC-2973; -. DR CPTAC; CPTAC-910; -. DR CPTAC; CPTAC-911; -. DR jPOST; Q9UHD2; -. DR MassIVE; Q9UHD2; -. DR PaxDb; 9606-ENSP00000329967; -. DR PeptideAtlas; Q9UHD2; -. DR ProteomicsDB; 84323; -. DR Pumba; Q9UHD2; -. DR Antibodypedia; 16584; 631 antibodies from 46 providers. DR DNASU; 29110; -. DR YCharOS; Q9UHD2; Tested 11 antibodies from 6 manufacturers. DR Ensembl; ENST00000331710.10; ENSP00000329967.5; ENSG00000183735.12. DR Ensembl; ENST00000650790.1; ENSP00000498995.1; ENSG00000183735.12. DR GeneID; 29110; -. DR KEGG; hsa:29110; -. DR MANE-Select; ENST00000331710.10; ENSP00000329967.5; NM_013254.4; NP_037386.1. DR UCSC; uc001ssc.3; human. DR AGR; HGNC:11584; -. DR CIViC; 29110; 1 evidence item across 1 molecular profile. DR ClinPGx; PA36348; -. DR CTD; 29110; -. DR DisGeNET; 29110; -. DR GeneCards; TBK1; -. DR HGNC; HGNC:11584; TBK1. DR HPA; ENSG00000183735; Low tissue specificity. DR MalaCards; TBK1; -. DR MIM; 177700; phenotype. DR MIM; 604834; gene. DR MIM; 616439; phenotype. DR MIM; 617900; phenotype. DR MIM; 620880; phenotype. DR OpenTargets; ENSG00000183735; -. DR Orphanet; 803; Amyotrophic lateral sclerosis. DR Orphanet; 275872; Frontotemporal dementia with motor neuron disease. DR Orphanet; 1930; Herpes simplex virus encephalitis. DR VEuPathDB; HostDB:ENSG00000183735; -. DR eggNOG; KOG4250; Eukaryota. DR GeneTree; ENSGT00950000182937; -. DR HOGENOM; CLU_000288_101_1_1; -. DR InParanoid; Q9UHD2; -. DR OMA; WSADMPV; -. DR OrthoDB; 10013850at2759; -. DR PAN-GO; Q9UHD2; 3 GO annotations based on evolutionary models. DR PhylomeDB; Q9UHD2; -. DR PathwayCommons; Q9UHD2; -. DR Reactome; R-HSA-1606341; IRF3 mediated activation of type 1 IFN. DR Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta. DR Reactome; R-HSA-3134975; Regulation of innate immune responses to cytosolic DNA. DR Reactome; R-HSA-3249367; STAT6-mediated induction of chemokines. DR Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN. DR Reactome; R-HSA-5205685; PINK1-PRKN Mediated Mitophagy. DR Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling. DR Reactome; R-HSA-5357905; Regulation of TNFR1 signaling. DR Reactome; R-HSA-9008059; Interleukin-37 signaling. DR Reactome; R-HSA-9013973; TICAM1-dependent activation of IRF3/IRF7. DR Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway. DR Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation. DR Reactome; R-HSA-936440; Negative regulators of DDX58/IFIH1 signaling. DR Reactome; R-HSA-936964; Activation of IRF3, IRF7 mediated by TBK1, IKKEpsilon (IKBKE). DR Reactome; R-HSA-9679191; Potential therapeutics for SARS. DR Reactome; R-HSA-9692916; SARS-CoV-1 activates/modulates innate immune responses. DR Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses. DR Reactome; R-HSA-9824878; Regulation of TBK1, IKKEpsilon (IKBKE)-mediated activation of IRF3, IRF7. DR Reactome; R-HSA-9828211; Regulation of TBK1, IKKEpsilon-mediated activation of IRF3, IRF7 upon TLR3 ligation. DR SABIO-RK; Q9UHD2; -. DR SignaLink; Q9UHD2; -. DR SIGNOR; Q9UHD2; -. DR Agora; ENSG00000183735; -. DR BioGRID-ORCS; 29110; 34 hits in 1203 CRISPR screens. DR CD-CODE; 7F558BCC; STING phase-separator. DR CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities. DR ChiTaRS; TBK1; human. DR EvolutionaryTrace; Q9UHD2; -. DR GeneWiki; TANK-binding_kinase_1; -. DR GenomeRNAi; 29110; -. DR Pharos; Q9UHD2; Tchem. DR PRO; PR:Q9UHD2; -. DR Proteomes; UP000005640; Chromosome 12. DR RNAct; Q9UHD2; protein. DR Bgee; ENSG00000183735; Expressed in colonic epithelium and 198 other cell types or tissues. DR ExpressionAtlas; Q9UHD2; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IDA:UniProtKB. DR GO; GO:0005829; C:cytosol; IDA:UniProt. DR GO; GO:0005654; C:nucleoplasm; IDA:HPA. DR GO; GO:1902554; C:serine/threonine protein kinase complex; NAS:ComplexPortal. DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0003676; F:nucleic acid binding; IEA:Ensembl. DR GO; GO:0051219; F:phosphoprotein binding; IPI:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; NAS:ProtInc. DR GO; GO:0019903; F:protein phosphatase binding; ISS:ARUK-UCL. DR GO; GO:0106310; F:protein serine kinase activity; IDA:BHF-UCL. DR GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB. DR GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:BHF-UCL. DR GO; GO:0002218; P:activation of innate immune response; IDA:UniProt. DR GO; GO:0140374; P:antiviral innate immune response; IDA:UniProt. DR GO; GO:0007249; P:canonical NF-kappaB signal transduction; TAS:UniProtKB. DR GO; GO:0140896; P:cGAS/STING signaling pathway; TAS:FlyBase. DR GO; GO:0002753; P:cytoplasmic pattern recognition receptor signaling pathway; IDA:UniProt. DR GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl. DR GO; GO:0051607; P:defense response to virus; NAS:ComplexPortal. DR GO; GO:0044565; P:dendritic cell proliferation; IEA:Ensembl. DR GO; GO:0006954; P:inflammatory response; TAS:UniProtKB. DR GO; GO:0045087; P:innate immune response; IDA:UniProtKB. DR GO; GO:0016236; P:macroautophagy; TAS:Reactome. DR GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl. DR GO; GO:1904262; P:negative regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:UniProtKB. DR GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:UniProtKB. DR GO; GO:0010508; P:positive regulation of autophagy; IDA:UniProt. DR GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; IEP:UniProtKB. DR GO; GO:0032727; P:positive regulation of interferon-alpha production; IDA:BHF-UCL. DR GO; GO:0032728; P:positive regulation of interferon-beta production; IDA:BHF-UCL. DR GO; GO:0016239; P:positive regulation of macroautophagy; IDA:HGNC. DR GO; GO:1904263; P:positive regulation of TORC1 signaling; IDA:UniProtKB. DR GO; GO:1904515; P:positive regulation of TORC2 signaling; ISS:UniProtKB. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL. DR GO; GO:0032481; P:positive regulation of type I interferon production; IDA:UniProt. DR GO; GO:0060340; P:positive regulation of type I interferon-mediated signaling pathway; IEA:Ensembl. DR GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl. DR GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB. DR GO; GO:0032479; P:regulation of type I interferon production; IDA:UniProtKB. DR GO; GO:0009615; P:response to virus; TAS:UniProtKB. DR GO; GO:0061470; P:T follicular helper cell differentiation; IDA:UniProt. DR GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IDA:UniProt. DR GO; GO:0060337; P:type I interferon-mediated signaling pathway; NAS:ComplexPortal. DR CDD; cd13988; STKc_TBK1; 1. DR CDD; cd21954; TBK1_C; 1. DR CDD; cd17127; Ubl_TBK1; 1. DR FunFam; 1.10.510.10:FF:000100; inhibitor of nuclear factor kappa-B kinase subunit epsilon; 1. DR FunFam; 1.20.1270.420:FF:000001; Serine/threonine-protein kinase TBK1; 1. DR FunFam; 3.30.200.20:FF:000106; serine/threonine-protein kinase TBK1 isoform X1; 1. DR FunFam; 3.10.20.90:FF:000112; TANK binding kinase TBK1; 1. DR Gene3D; 1.20.1270.420; -; 1. DR Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1. DR Gene3D; 3.30.200.20; Phosphorylase Kinase, domain 1; 1. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR051180; IKK. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR017441; Protein_kinase_ATP_BS. DR InterPro; IPR041309; TBK1_CC1. DR InterPro; IPR041087; TBK1_ULD. DR PANTHER; PTHR22969; IKB KINASE; 1. DR PANTHER; PTHR22969:SF14; SERINE_THREONINE-PROTEIN KINASE TBK1; 1. DR Pfam; PF00069; Pkinase; 1. DR Pfam; PF18394; TBK1_CCD1; 1. DR Pfam; PF18396; TBK1_ULD; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. PE 1: Evidence at protein level; KW 3D-structure; Amyotrophic lateral sclerosis; Antiviral defense; KW ATP-binding; Coiled coil; Cytoplasm; Disease variant; Glaucoma; KW Host-virus interaction; Immunity; Innate immunity; Isopeptide bond; Kinase; KW Methylation; Neurodegeneration; Nucleotide-binding; Phosphoprotein; KW Proteomics identification; Reference proteome; KW Serine/threonine-protein kinase; Transferase; Ubl conjugation. FT CHAIN 1..729 FT /note="Serine/threonine-protein kinase TBK1" FT /id="PRO_0000086743" FT DOMAIN 9..310 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT DOMAIN 309..385 FT /note="Ubiquitin-like" FT REGION 621..729 FT /note="Interaction with AZI2, TANK and TBKBP1" FT /evidence="ECO:0000269|PubMed:21931631" FT COILED 407..657 FT /evidence="ECO:0000250|UniProtKB:Q9WUN2" FT COILED 658..713 FT /evidence="ECO:0000255" FT ACT_SITE 135 FT /note="Proton acceptor" FT /evidence="ECO:0000305|PubMed:23453971, FT ECO:0000305|PubMed:23453972, ECO:0000305|PubMed:30842653" FT BINDING 15..23 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT BINDING 38 FT /ligand="ATP" FT /ligand_id="ChEBI:CHEBI:30616" FT /evidence="ECO:0000305" FT MOD_RES 172 FT /note="Phosphoserine; by autocatalysis and IKKB" FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23746807" FT MOD_RES 607 FT /note="N6-methyllysine; by SETD4" FT /evidence="ECO:0000269|PubMed:37926288" FT MOD_RES 716 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT CROSSLNK 30 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 401 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:23453971" FT CROSSLNK 670 FT /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with FT G-Cter in ubiquitin)" FT /evidence="ECO:0000269|PubMed:22388039, FT ECO:0000269|PubMed:27692986" FT VARIANT 24 FT /note="F -> S (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084111" FT VARIANT 47 FT /note="R -> H (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073938" FT VARIANT 50 FT /note="D -> A (in IIAE8; decreased expression levels; FT dbSNP:rs1010930015)" FT /evidence="ECO:0000269|PubMed:22851595" FT /id="VAR_080517" FT VARIANT 105 FT /note="Y -> C (in FTDALS4; dbSNP:rs1366668789)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073939" FT VARIANT 151 FT /note="S -> F (in dbSNP:rs55824172)" FT /evidence="ECO:0000269|PubMed:21447600" FT /id="VAR_069754" FT VARIANT 152 FT /note="V -> L (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084112" FT VARIANT 159 FT /note="G -> A (in IIAE8; loss of kinase activity; loss of FT autophosphorylation at S-172; loss of IFNB induction; FT dbSNP:rs1555202947)" FT /evidence="ECO:0000269|PubMed:22851595, FT ECO:0000269|PubMed:32972995" FT /id="VAR_080518" FT VARIANT 207 FT /note="I -> V (in IIAE8; uncertain significance; FT dbSNP:rs1555203557)" FT /evidence="ECO:0000269|PubMed:26513235" FT /id="VAR_080519" FT VARIANT 212 FT /note="Y -> D (in AIARV; likely pathogenic; severely FT decreased function in IRF3 phosphorylation and in positive FT regulation of type I interferon-mediated signaling pathway; FT does not rescue defective IRF3 phosphorylation on S-386 and FT IFN-1 stimulated gene expression in TBK1-deficient patient FT cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089908" FT VARIANT 271 FT /note="R -> Q (in dbSNP:rs56196591)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041208" FT VARIANT 291 FT /note="K -> E (in dbSNP:rs34774243)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041209" FT VARIANT 296 FT /note="D -> H (in a breast pleomorphic lobular carcinoma FT sample; somatic mutation)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041210" FT VARIANT 305 FT /note="I -> T (in FTDALS4; dbSNP:rs770942184)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073940" FT VARIANT 306 FT /note="L -> I (in FTDALS4; uncertain significance; FT dbSNP:rs201970436)" FT /evidence="ECO:0000269|PubMed:21447600, FT ECO:0000269|PubMed:25943890" FT /id="VAR_069755" FT VARIANT 308..729 FT /note="Missing (loss of IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084113" FT VARIANT 308 FT /note="R -> Q (in FTDALS4; reduced kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073941" FT VARIANT 357 FT /note="R -> Q (in FTDALS4; reduced kinase activity; FT dbSNP:rs758357594)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073942" FT VARIANT 384 FT /note="R -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084114" FT VARIANT 388 FT /note="N -> D (in dbSNP:rs17857028)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024746" FT VARIANT 388 FT /note="N -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084115" FT VARIANT 397 FT /note="I -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084116" FT VARIANT 401 FT /note="K -> E (in FTDALS4; dbSNP:rs756751089)" FT /evidence="ECO:0000269|PubMed:25943890" FT /id="VAR_073943" FT VARIANT 410 FT /note="G -> R (in a colorectal adenocarcinoma sample; FT somatic mutation; dbSNP:rs1262765773)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041211" FT VARIANT 440..729 FT /note="Missing (in AIARV; pathogenic)" FT /evidence="ECO:0000269|PubMed:32447396, FT ECO:0000269|PubMed:34363755" FT /id="VAR_089909" FT VARIANT 464 FT /note="V -> A (in dbSNP:rs35635889)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:21447600" FT /id="VAR_041212" FT VARIANT 508 FT /note="L -> I (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084117" FT VARIANT 522 FT /note="I -> M (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084118" FT VARIANT 533 FT /note="A -> T (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084119" FT VARIANT 559 FT /note="M -> R (in FTDALS4; loss of kinase activity)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073944" FT VARIANT 570 FT /note="K -> Q (in dbSNP:rs17853341)" FT /evidence="ECO:0000269|PubMed:15489334" FT /id="VAR_024747" FT VARIANT 571 FT /note="A -> V (in FTDALS4; dbSNP:rs765035140)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073945" FT VARIANT 598 FT /note="M -> V (in FTDALS4; dbSNP:rs899858451)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073946" FT VARIANT 619..729 FT /note="Missing (in AIARV; pathogenic; homozygous patient- FT derived cells show high rates of cell death; loss of FT protein expression in homozygous patient cells)" FT /evidence="ECO:0000269|PubMed:34363755" FT /id="VAR_089910" FT VARIANT 643 FT /note="Missing (in FTDALS4)" FT /evidence="ECO:0000269|PubMed:25803835" FT /id="VAR_073947" FT VARIANT 653 FT /note="E -> Q (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084120" FT VARIANT 659 FT /note="P -> S (no effect on IFNB induction)" FT /evidence="ECO:0000269|PubMed:32972995" FT /id="VAR_084121" FT VARIANT 696 FT /note="E -> K (in FTDALS4; loss of kinase activity; impairs FT binding to OPTN; dbSNP:rs748112833)" FT /evidence="ECO:0000269|PubMed:25803835, FT ECO:0000269|PubMed:25943890" FT /id="VAR_073948" FT MUTAGEN 30 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-401." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 33 FT /note="D->A: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 38 FT /note="K->A: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:10581243, FT ECO:0000269|PubMed:22851595, ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:29150432, FT ECO:0000269|PubMed:31530866, ECO:0000269|PubMed:31709703" FT MUTAGEN 135 FT /note="D->N: Loss of kinase activity." FT /evidence="ECO:0000269|PubMed:21931631, FT ECO:0000269|PubMed:23453971, ECO:0000269|PubMed:23453972, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 172 FT /note="S->A: Loss of kinase activity. No effect on FT dimerization. Loss of USP38-mediated degradation." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972, ECO:0000269|PubMed:27692986" FT MUTAGEN 172 FT /note="S->E: Decreased kinase activity." FT /evidence="ECO:0000269|PubMed:11839743, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 316 FT /note="L->E: Decreases kinase activity. No effect on FT phosphorylation." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 325 FT /note="Y->E: Abolishes phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 355 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with A-357 or R- FT 448." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:23453972" FT MUTAGEN 357 FT /note="R->A: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 401 FT /note="K->R: Decreases ubiquitination. Abolishes FT ubiquitination, phosphorylation and kinase activity; when FT associated with R-30." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 448 FT /note="E->R: Decreases phosphorylation and kinase activity. FT Abolishes dimerization; when associated with R-355." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 459 FT /note="H->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-466 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 466 FT /note="I->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-470." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 470 FT /note="F->E: Abolishes dimerization and decreases kinase FT activity but no effect on phosphorylation; when associated FT with E-459 and E-466." FT /evidence="ECO:0000269|PubMed:23453972" FT MUTAGEN 547 FT /note="R->D: Decreases phosphorylation and kinase activity. FT Abolishes dimerization." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 577 FT /note="Y->A: Decreases kinase activity. Reduced FT phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:23453971, FT ECO:0000269|PubMed:30842653" FT MUTAGEN 578 FT /note="N->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 580 FT /note="E->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 581 FT /note="Q->A: Reduced phosphorylation of STING1." FT /evidence="ECO:0000269|PubMed:30842653" FT MUTAGEN 582 FT /note="I->A: Decreases kinase activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 584 FT /note="K->A: Decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 589 FT /note="K->D: Decreases phosphorylation and kinase FT activity." FT /evidence="ECO:0000269|PubMed:23453971" FT MUTAGEN 607 FT /note="K->A,R: Attenuated homodimerization during Sendai FT virus infection; decreased interaction with IRF3 or MAVS; FT decreased IFNB1 promoter activation." FT /evidence="ECO:0000269|PubMed:37926288" FT MUTAGEN 670 FT /note="K->R: Abrogates both 'Lys-48'-linked and 'Lys-33'- FT linked ubiquitination." FT /evidence="ECO:0000269|PubMed:27692986" FT MUTAGEN 690 FT /note="M->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 693 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 694 FT /note="K->E: Strongly decreases interaction with TANK and FT TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 704 FT /note="L->A: Strongly decreases interaction with AZI2, TANK FT and TBKBP1. No effect on phosphorylation." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 708 FT /note="N->A: Decreases interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT MUTAGEN 711 FT /note="L->A: Almost abolishes interaction with TANK." FT /evidence="ECO:0000269|PubMed:21931631" FT STRAND 1..3 FT /evidence="ECO:0007829|PDB:6CQ0" FT STRAND 5..17 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 19..28 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 29..31 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 34..40 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 42..46 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 49..61 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 65..67 FT /evidence="ECO:0007829|PDB:4IWO" FT STRAND 70..75 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 77..79 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 82..87 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 94..99 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 101..103 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 109..128 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 138..140 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 141..145 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 151..155 FT /evidence="ECO:0007829|PDB:4EUU" FT TURN 161..163 FT /evidence="ECO:0007829|PDB:4IWQ" FT HELIX 167..169 FT /evidence="ECO:0007829|PDB:4EUT" FT STRAND 173..175 FT /evidence="ECO:0007829|PDB:4EUT" FT HELIX 177..179 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 182..188 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 202..216 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 220..222 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 227..229 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 231..240 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 247..250 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 252..254 FT /evidence="ECO:0007829|PDB:6NT9" FT STRAND 257..262 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 271..284 FT /evidence="ECO:0007829|PDB:4EUU" FT STRAND 285..287 FT /evidence="ECO:0007829|PDB:4IWP" FT TURN 289..291 FT /evidence="ECO:0007829|PDB:4EUU" FT HELIX 305..307 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 308..315 FT /evidence="ECO:0007829|PDB:4EFO" FT TURN 316..319 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 320..327 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 332..343 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 347..349 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 350..354 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 357..359 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 367..369 FT /evidence="ECO:0007829|PDB:4EFO" FT STRAND 375..377 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 379..383 FT /evidence="ECO:0007829|PDB:4EFO" FT HELIX 408..480 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 498..526 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 527..529 FT /evidence="ECO:0007829|PDB:6RSU" FT STRAND 530..532 FT /evidence="ECO:0007829|PDB:4IWO" FT HELIX 535..539 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 544..546 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 548..571 FT /evidence="ECO:0007829|PDB:4IM0" FT STRAND 572..574 FT /evidence="ECO:0007829|PDB:6O8B" FT HELIX 577..603 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 605..647 FT /evidence="ECO:0007829|PDB:4IM0" FT TURN 648..651 FT /evidence="ECO:0007829|PDB:4IM0" FT HELIX 680..714 FT /evidence="ECO:0007829|PDB:5EP6" FT STRAND 715..717 FT /evidence="ECO:0007829|PDB:5EP6" SQ SEQUENCE 729 AA; 83642 MW; B58E4FE1B502276D CRC64; MQSTSNHLWL LSDILGQGAT ANVFRGRHKK TGDLFAIKVF NNISFLRPVD VQMREFEVLK KLNHKNIVKL FAIEEETTTR HKVLIMEFCP CGSLYTVLEE PSNAYGLPES EFLIVLRDVV GGMNHLRENG IVHRDIKPGN IMRVIGEDGQ SVYKLTDFGA ARELEDDEQF VSLYGTEEYL HPDMYERAVL RKDHQKKYGA TVDLWSIGVT FYHAATGSLP FRPFEGPRRN KEVMYKIITG KPSGAISGVQ KAENGPIDWS GDMPVSCSLS RGLQVLLTPV LANILEADQE KCWGFDQFFA ETSDILHRMV IHVFSLQQMT AHKIYIHSYN TATIFHELVY KQTKIISSNQ ELIYEGRRLV LEPGRLAQHF PKTTEENPIF VVSREPLNTI GLIYEKISLP KVHPRYDLDG DASMAKAITG VVCYACRIAS TLLLYQELMR KGIRWLIELI KDDYNETVHK KTEVVITLDF CIRNIEKTVK VYEKLMKINL EAAELGEISD IHTKLLRLSS SQGTIETSLQ DIDSRLSPGG SLADAWAHQE GTHPKDRNVE KLQVLLNCMT EIYYQFKKDK AERRLAYNEE QIHKFDKQKL YYHATKAMTH FTDECVKKYE AFLNKSEEWI RKMLHLRKQL LSLTNQCFDI EEEVSKYQEY TNELQETLPQ KMFTASSGIK HTMTPIYPSS NTLVEMTLGM KKLKEEMEGV VKELAENNHI LERFGSLTMD GGLRNVDCL //